

May 26, 2025

То	То
Listing Department,	The Corporate Relations Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED	BSE LIMITED
Exchange Plaza,	Phiroz Jeejeebhoy Towers,
Bandra Kurla Complex, Bandra (E),	25 <sup>th</sup> floor, Dalal Street,
MUMBAI -400 051	MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sir / Madam,

## Sub: Outcome of the Board Meeting held on May 26, 2025.

The Board of Directors of the Company at its meeting held today, May 26, 2025, has, inter alia, considered and approved: -

(a) the standalone and consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2025, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Audited Financial Results of the Company along with the Auditors Reports issued by the Statutory Auditors.

Pursuant to Regulation 33(3)(d) of SEBI Listing Regulations, we hereby confirm and declare that the Statutory Auditors of the Company, M/s. Deloitte Haskins & Sells, Chartered Accountants, have issued the audit reports on Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2025, with unmodified opinion.

(b) to seek approval of the members regarding enhancement of the existing limits under Section 186 of the Companies Act, 2013 through Postal Ballot. The Postal Ballot Notice shall be sent to the members in due course and the same shall be submitted to the stock exchanges.

(c) the appointment of M/s. MRR & Associates, Company Secretaries in Practice as the Secretarial Auditors of the Company for a term of five consecutive years commencing from FY 2025-26, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting. Additional information as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations is enclosed as Annexure.

The Board meeting commenced at 4.00 p.m. and concluded at 6.00 p.m.

Please take the information on record.

Yours faithfully, For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

Encl: as above.

(CIN: L24239TG1986PLC015190)

# AUROBINDO PHARMA LIMITED

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com

## ි AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

www.aurobindo.com

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com

(All amounts are in ₹ million, unless otherwise stated)

	STATEMENT OF AUDITED STANDALONE FINA		•		MD	
	UNAUDITED STANDALONE FINANCIAL RI					
			Quarter ended		Year er	ded
	Particulars	31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
		Unaudited	Unaudited	Unaudited	Audited	Audited
_		(Refer note 6)		(Refer note 6)		
A	Continuing Operations:					
1	Revenue from operations					
	(a) Net sales/ income from operations	27,214.3	28,835.6	28,664.0	1,07,880.9	1,05,422.
	(b) Other operating income	105.6	330.7	276.3	1,452.1	1,034.
	Total revenue from operations	27,319.9	29,166.3	28,940.3	1,09,333.0	1,06,456.
2	Other income					
	(a) Foreign exchange gain (net)	501.4	-	3.8	1,181.1	942
	(b) Others	638.4	542.6	1,225.9	2,100.1	5,218
	Total other income	1,139.8	542.6	1,229.7	3,281.2	6,160
3	Total income (1+2)	28,459.7	29,708.9	30,170.0	1,12,614.2	1,12,617.
4	Expenses					
	(a) Cost of materials consumed	13,607.0	15,065.9	14,015.6	56,102.1	57,610
	(b) Purchase of stock-in-trade	163.1	190.6	170.1	651.3	2,034
	(c) Changes in inventories of finished goods, stock-in-trade and	605.2	(613.7)	(131.0)	(676.6)	(1,162
	work-in-progress					
	(d) Employee benefits expense	2,731.1	2,651.5	2,489.1	10,630.7	9,805
	(e) Finance costs	610.9	661.9	530.7	2,300.4	1,826
	(f) Foreign exchange loss (net)		281.0		( <b>1</b> )	1
	(g) Depreciation and amortisation expenses	938.8	682.8	648.1	2,972.0	2,545
	(h) Other expenses	4,248.4	4,459.5	4,648.6	17,049.8	15,927
	Total expenses	22,904.5	23,379.5	22,371.2	89,029.7	88,587
	Profit before tax from continuing operations (3-4)	5,555.2	6,329.4	7,798.8	23,584.5	24,029
6	Tax expense					
	Current tax	1,552.5	1,640.3	2,076.6	6,273.7	5,980
	Deferred tax	(79.0)	(31.4)	(64.5)	(157.1)	(952
_	Total tax expense	1,473.5	1,608.9	2,012.1	6,116.6	5,028
	Profit from continuing operations (5-6)	4,081.7	4,720.5	5,786.7	17,467.9	19,001
	Discontinued Operations: (Refer note 4)					
100	Profit before tax from discontinued operations			<u> </u>	(*) 	724
	Tax expense from discontinued operations		1.6	-		184
	Profit from discontinued operations (8-9)	4 001 7	4 720 5	5 706 7	17 467 0	540
	Profit after tax (7+10) Other comprehensive income	4,081.7	4,720.5	5,786.7	17,467.9	19,541
12						
	Items that will not to be reclassified subsequently to profit or loss:	(12.1)	(10.4)	(4.0)	(70.3)	(25
	(a) Re-measurement of defined benefit liability	(12.1)	(19.4)	(4.8)	(70.3)	(22
	(b) Income-tax relating to items that will not be reclassified to profit or loss	3.0	4.9	1.2	17.7	5
	loss	(0.4)	(145)	(2.5)	150.01	
	Other comprehensive loss	(9.1)	(14.5)	(3.6)	(52.6)	(16
- 11	Total comprehensive income (11+12)	4,072.6	4,706.0	5,783.1	17,415.3	19,524
	Paid-up equity share capital (face value ₹ 1 per share) (Refer note 5) Other equity	580.8	580.8	585.9	580.8	585
	Earnings per equity share from continuing operations (face value ₹ 1	(Net en eurolise d)	(Net an average of the set)	(NI-4	2,04,760.3	1,96,642
	per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)	(Annualise
_	(a) Basic (in ₹)	7.03	8.13	9.88	29.97	22
	(b) Diluted (in ₹)	7.03	8.13	9.88	29.97	32.4 32.4
	Earnings per equity share from discontinued operations (face value ₹1				(Annualised)	Annualise
	per share)		(not annualiseu)	(not annuanseu)	(Annualiscu)	(Annualise
	(a) Basic (in ₹)	(4)			2	0,
	(b) Diluted (in ₹)	12				0.
	Earnings per equity share from total operations (face value ₹ 1 per					
	share)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)	(Annualise
- 1	(a) Basic (in ₹)	7.03	8.13	9.88	29.97	33.
- 1	(b) Diluted (in ₹)	7.03	8.13	9.88	29.97	33.



OO PHARA AUROR к...- У DERAB

### Standalone Balance Sheet

- 0	ATL	1. INC. 18	102252	- XT	Sec. 1
	All amounts are	In K mi	mon, unless	otherwise	stated)

	(All amounts are in	< million, unless of	herwise stated)
SI.	Particulars	As at	As at
No.	Particulars	31.03.2025	31.03.2024
		Audited	Audited
-			
	ASSETS		
	Non-current assets		
T			
	Property, plant and equipment	21,664.9	21,853.0
	Capital work-in-progress	875.3	1,326.8
	Right-of-use assets	188.0	369.1
	Goodwill	917.0	917.0
	Other intangible assets	598.1	1,052.2
1 0	Financial assets		_/
	Investments	1,52,095.6	1 22 024 2
			1,33,934.3
	Loans	16,543.2	14,294.7
	Trade receivables	-	-
	Other financial assets	431.6	391.6
	Income tax assets (net)	2,791.5	2,753.0
	Other non-current assets	2,131.4	2,256.8
	Total non-current assets	1,98,236.6	1,79,148.5
		2,50,200.0	1,75,145,5
1	Current assets		
۲ I			
	Inventories	23,592.8	23,676.0
	Financial assets		
	Investments	0.1	0.1
	Trade receivables	41,950.5	37,765.9
	Cash and cash equivalents	2,952.6	833.2
	Bank balances other than cash and cash equivalents	31.0	110.2
	Loans	54.4	
	Other financial assets	100 000 000 000	46.0
		2,062.7	2,233.2
	Other current assets	6,249.9	7,726.7
	Total current assets	76,894.0	72,391.3
	TOTAL ASSETS (1+2)	2,75,130.6	2,51,539.8
		2,73,130.0	2,51,555.0
	EQUITY AND LIABILITIES		
11	Equity		
	Equity share capital	580.8	585.9
	Other equity	2,04,760.3	1,96,642.3
	Total equity	2,05,341.1	1,97,228.2
	Liabilities		
2	Non-current liabilities		
1	Financial liabilities		
		4 000 0	
	Borrowings	4,000.0	
	Lease liabilities	37.2	215.1
	Provisions	533.0	460.0
	Deferred tax liability (net)	1,014.3	1,189.1
	Total non-current liabilities	5,584.5	1,864.2
		*	
3	Current liabilities		
	Financial liabilities		
	Borrowings	43.350.0	20 170 4
		42,250.9	28,178.4
	Lease liabilities	177.9	213.9
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises	378.4	389.3
	total outstanding dues of creditors other than micro enterprises and small enterprises	17,495.8	17,503.0
	Other financial liabilities	2,761.5	4,171.0
	Other current liabilities	290.4	795.3
	Provisions		
		213.5	180.3
	Current tax liabilities (net)	636.6	1,016.2
		State State State	
	Total current liabilities	64,205.0	52,447.4
	TOTAL EQUITY AND LIABILITIES (1+2+3)	2,75,130.6	2,51,539.8





(All amounts are in ₹ million	unlace otherwise stated)
THE BUILD BE BE THE CHILLED	1, Unices otherwise stateor

	(All amounts are in		and the second se
SI.		For the year	For the year
No.	Particulars	ended	ended
		31.03.2025	31.03.2024
		Audited	Audited
1	CASH FLOW FROM OPERATING ACTIVITIES		
	Net profit before tax		
	from continuing operations	23,584.5	24,029.2
	from discontinued operations	÷	724.9
	Adjustments for :		
	Depreciation and amortisation expenses	2,972.0	3,486.6
	Allowance for expected credit losses (net)	49.8	114.5
	Provision for diminution of investment	137.6	328.5
	Provisions no longer required written back	(25.4)	(3.4)
	Unrealised foreign exchange gain on non derivative assets (net)	(700.1)	(381.1)
	Mark-to-market gain on derivative foreign currency forward contracts	(152.9)	(1.3)
	Profit on sale of property, plant and equipment (net)	(21.0)	(14.3)
	Dividend income		(2,646.7)
	Profit on sale of investments	(53.8)	(27.8)
	Finance costs	2,286.5	2,153.7
	Interest income	(1,651.5)	(2,312.6)
I 1	Operating profit before working capital changes	26,425.7	25,450.2
	Movements in working capital:		
	(Increase)/decrease in trade receivables	(3,500.9)	(7,435.9)
	(Increase)/decrease in inventories	83.2	(3,083.4)
1	(Increase)/decrease in loans	(11.7)	(11.1)
	(Increase)/decrease in other financial assets	114.8	(1,107.6)
	(Increase)/decrease in other assets	1,610.5	(2,023.0)
1	Increase/(decrease) in trade payables	(42.9)	7,519.0
I 1	Increase/(decrease) in provision for employee benefits	35.9	83.8
	Increase/(decrease) in other financial liabilities	(1,060.2)	3,735.3
	Increase/(decrease) in other liabilities	(504.9)	42,5
I 1	Cash generated from operating activities	23,149.5	23,169.8
I 1	Income-tax paid (net)	(6,691.6)	(6,021.8)
	Net cash flow generated from operating activities (A)	16,457.9	17,148.0
I 1			
2	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of property, plant and equipment including movement in capital work-in-	(2,469.4)	(4,175.9)
1	progress, capital advances and capital creditors		
I 1	Purchase of intangible assets	27.	(01.0)
1	Proceeds from sale of property, plant and equipment	FEAR	(91.6)
1	Purchase of non-current investments	554.5	46.8
I 1	Proceeds from redemption of debentures	(16,125.1)	a see serve weeperk
I 1	Proceeds from sale of non-current investments	11,000.0	7,750.0
	Profit from sale of current investments	5.0	119.2
I 1	Consideration on slump sale (refer note 4)	53.8	38,948.2
	Dividend received from subsidiaries		÷ .
	Loans made to subsidiaries	(10 110 0)	2,646.7
	Loans repaid by subsidiaries	(18,110.0) 3,585.8	(23,453.5)
	Interest received		
	Movement in other bank balances (net)	772.3	1,995.1
1	Net cash flow used in investing activities (B)	79.1 (20,659.0)	52.7
1		(20,059.0)	(1,599.6)
2	CASH FLOW FROM FINANCING ACTIVITIES		
ا ا	Buy back of equity shares (including tax and transaction cost)	(0.202.4)	
	Proceeds from non current borrowings	(9,302.4) 12,000.0	676 
	Repayment of non current borrowings	Reg and the	2.6
	Proceeds/(repayment) of current borrowings (net)	(300.0)	(12 410 6)
	Repayment of lease liabilities	6,232.9	(13,419.6)
	Interest paid	(239.3)	(217.1)
	Movement in unclaimed dividend	(2,222.7)	(2,097.2)
		(5.4)	(2,636.4)
	Net cash generated from/(used in) financing activities (C)	6,163.1	(18,370.3)
	Net Increase/(decrease) in cash and cash equivalents (A+B+C)	1,962.0	(2,821.9)
	Cash and cash equivalents at the beginning of the year	833.2	3,571.3
	Effect of exchange differences on cash and cash equivalents	157.4	83.8
	Cook and each assimption of the and of the summ		
-	Cash and cash equivalents at the end of the year	2,952.6	833,2
	Cash and cash equivalents comprises of:		
	Cash on hand	0.6	0.5
	Balance with banks:		
	Current accounts	2,952.0	832.7
	Cash and cash powinglants considered for each flows		
	Cash and cash equivalents considered for cash flows	2,952.6	833.2
	ASKIA		



PHARA 0 k...- y AUROR, 5 MOERABAD

#### NOTES:

- 1 The above standalone financial results of Aurobindo Pharma Limited ("the Company") has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above standalone financial results of the Company as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on May 26, 2025. The results for the year ended March 31, 2025 has been audited and for the quarter ended March 31, 2025 has been reviewed by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31, 2025 and have issued an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2025.
- 3 The Company operates in only one reportable segment viz., 'Pharmaceuticals ' in accordance with Ind AS 108, "Operating Segment".
- 4 The Company transferred certain Active Pharmaceutical Ingredients (API) business units to its wholly owned subsidiary, Apitoria Pharma Private Limited (formerly known as Auro Pharma India Private Limited) (APPL) on a going concern basis by way of slump sale with effect from October 1, 2023. Accordingly, disclosures as required under Indian Accounting Standard (Ind AS) 105 "Non-Current Assets Held for Sale and Discontinued Operations", in the standalone financial results for all the periods have been suitably presented.

Key financials information of discontinued operations:

₹ in million

Particulars		Quarter ended			Year ended	
	31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024	
Total Income	5.		(*		24,183.	
Total expenses	10	-	14	-	23,458.	
Profit before tax	12	-		-	724.	
Total tax expense	54 (S)	9	12	-	184.	
Net profit for the period	-	-		-	540.	

5 The Board of Directors at their meeting held on July 18, 2024, approved buyback of 5,136,986 fully paid-up equity shares of face value of ₹ 1 each (representing 0.88% of the total number of equity share shares of the Company) for an aggregate value not exceeding ₹ 7,500.0 million (buyback size) (excluding transaction cost and tax on buyback) at a maximum buyback price of ₹ 1,460/- per equity share. Upon completion of the buyback, the Company extinguished the equity shares in compliance with applicable rules and regulations.

Consequently, the paid up equity share capital was reduced by ₹ 5.1 million. The aggregate amount paid for buyback was ₹ 9,302.4 million including tax and related expenses.

6 The figures for the current quarter and quarter ended March 31, 2024, are the balancing figures between the audited figures in respect of full financial year ended March 31, 2025 and March 31, 2024, respectively and published year to date figures up to third quarter ended December 31, 2024 and December 31, 2023, respectively, which were subject to limited review by the statutory auditors.



By Order of the Board For Aurobindo Pharma Limited

16 . - 1



Place: Hyderabad Date : May 26, 2025 K.Nithyananda Reddy Vice Chairman & Managing Director DIN-01284195

Chartered Accountants Meenakshi Pride Rock Tower III [Block – M], 8th & 9th floors Survey No. 23, Gachibowli Serilingampally Municipality Ranga Reddy District Hyderabad-500032 Telangana, India

# INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

## **Opinion and Conclusion**

We have (a) audited the Standalone Financial Results for the year ended March 31, 2025 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2025 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Audited Standalone Financial Results for the Year ended March 31, 2025 and Unaudited Standalone Financial Results for the Quarter ended March 31, 2025" of **AUROBINDO PHARMA LIMITED** (the "Company"), (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

## (a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2025:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year then ended.

## (b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2025

With respect to the Standalone Financial Results for the quarter ended March 31, 2025, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

# Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.



Page 1 of 4

## Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2025 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2025 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

## **Auditor's Responsibilities**

## (a) Audit of the Standalone Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## (b) Review of the Standalone Financial Results for the quarter ended March 31, 2025

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under Section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

## **Other Matters**

The Statement includes the results for the Quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our report on the Statement is not modified in respect of this matter.

For DELOITTE HASKINS & SELLS

Chartered Accountants (Firm's Registration No. 008072S)

C Manish Muralidhar Partner (Membership No.213649) (UDIN: 25213649BMOENJ1709)

Place: Hyderabad Date: May 26, 2025





### AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190) www.aurobindo.com

Regd. Office: Plot No.2, Maitrivinar, Amerynet, Hyder add - 500 38, India Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com (All amounts are in * million; unless or UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR TKER ENDED MARCH 31, 2025 AND UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR TKER ENDED MARCH 31, 2025         Quarter ended Veare Variation of the provide the construction of	
(All amounts are in K million, unless or STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR YEAR ENDED MARCH 31, 2025 AND UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2025           Quarter ended         Year e           Quarter ended         Year e <th colspa<="" th=""></th>	
STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR YEAR ENDED MARCH 31, 2025 AND UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2025           Quarter ende         Year e           Quarter ende         Year e           Particulars         Quarter ende         Year e           Quarter ende         Quarter ende         Quarter ende         Year e           Inaudited         Unaudited         Quarter ende         Quarter ende         Year e           Inaudited         Unaudited         Quarter ende           Inaudited         Quarter ende         Quarter ende         Quarter ende         Quarter ende         Quarter ende	
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2025           Quarter ended         Year ended           Quarter ended         Year ended           Bill 30.2025         31.03.2024         31.03.2025           All 30.3.2025         31.03.2026         Jul 30.3.2025           Image: State of the operating income         Unaudited         Unaudited         Value           Image: State of the operating income         Bill 30.2025         Total revenue from operations         Bi3,811.2         78,931.5         74,919.2         3,13,781.3           Total revenue from operations         Bi3,821.2         79,785.2         75,801.5         3,13,721.3           Total revenue from operations         Bi3,821.2         79,785.2         75,801.5         3,13,721.3           2         Other income         1         2.2         75,801.5         6,218.5           Total revenue from operations         Bi3,851.1         77,97.57.	
Particulars         Quarter ended         Year e           31.03.2025         31.03.2024         31.03.2024         31.03.2025         31.03.2024         31.03.2025           Unaudited         Unaudited         Unaudited         Madited         Audited           (a) Net sales/ income from operations         83,811.2         78,931.5         74,919.2         3,13,781.3           (b) Other operating income         10.0         853.7         882.3         3,456.0           1 Total revenue from operations         83,821.2         79,785.2         75,801.5         3,17,237.3           2 Other income         116.0         -         -         -         -           (a) Foreign exchange gain (net)         1,157.9         1,356.2         6,218.5         71,577.7         3,23,455.8           1 total other income         1,348.1         1,572.9         1,356.2         6,218.5         71,577.7         3,23,455.8           1 cost of materials consumed         (a) Cost of materials consumed         (b) Purchase of stock-in-trade         6,361.8         8,238.9         7,859.5         2,871.1           (c) Changes in inventories of finished goods, stock-in-trade and work-in-progress         11,626.4         11,315.5         10,263.2         44,756.2           (d) Employce benefits expense	
Particulars         31.03.2025         31.12.2024         31.03.2024         31.03.2025           Unaudited         Unaudited         Unaudited         Unaudited         Audited           I         Revenue from operations         (Refer note 8)         -         -           (a) Net sales/ income from operations         83,811.2         78,931.5         74,919.2         3,13,781.3           (b) Other operating income         10.0         853.7         882.3         3,456.0           Total revenue from operations         83,812.2         79,785.2         75,801.5         3,17,237.3           2 Other income         116.0         -         -         -         -           (a) Foreign exchange gain (net)         1,232.1         1,572.9         1,356.2         6,218.5           Total other income         1,348.1         1,572.9         1,356.2         6,218.5           Total income (1+2)         85,169.3         81,358.1         77,157.7         3,23,455.8           3 Expenses         -	
Unaudited (Refer note 8)         Unaudited (Refer note 8)         Unaudited (Refer note 8)         Audited           1         Revenue from operations (a) Net sales/ income from operations         83,811.2         78,931.5         74,919.2         3,13,781.3           2         Other operating income         10.0         853.7         882.3         3,466.0           Total revenue from operations         83,811.2         79,785.2         75,801.5         3,17,237.3           2         Other income (a) Foreign exchange gain (net)         116.0         -         -         -           (b) Others         1,348.1         1,572.9         1,356.2         6,218.5         70.218.5           Total income (1+2)         85,169.3         81,358.1         77,177.7         3,23,455.8           3         Expenses         -         -         -           (d) Cost of materials consumed (b) Purchase of stock-in-trade (b) Purchase of stock-in-trade         6,361.8         8,238.9         7,859.5         28,871.1           (c) Changes in inventories of finished goods, stock-in-trade and work-in-progress         -         488.3         142.8         27,263.2         44,756.2           (d) Employee benefits expense         11,626.4         11,315.5         10.263.2         44,756.2           (f) Foreign excha	
Image: space	
1       Revenue from operations <ul> <li>(a) Net sales/ income from operations</li> <li>(b) Other operating income</li> <li>(c) Net sales/ income</li> <li>(c) Other operating income</li> <li>(d) Other operating income</li> <li>(e) Other operating income</li> <li>(f) Other operating income</li> <li>(g) Poreign exchange gain (net)</li> <li>(h) Others</li> <li>(h) Purchase of stock-in-trade</li> <li>(h) Foreign exchange loss (net)</li> <li>(h) Engleve benefits expense</li> <li>(h) Other expenses</li> <li>(h) Other expenses</li> <li>(h) Other expenses</li> <li>(h) Other expenses</li> <li>(h)</li></ul>	
(a) Net sales/ income from operations       83,811.2       78,931.5       74,919.2       3,13,781.3         (b) Other operating income       10.0       853.7       882.3       3,456.0         Total revenue from operations       83,821.2       79,785.2       75,801.5       3,17,237.3         2       Other income       116.0       -       -       -         (a) Foreign exchange gain (net)       116.0       -       -       -         (b) Others       1,232.1       1,572.9       1,356.2       6,218.5         Total income (1+2)       13,348.1       1,572.9       1,356.2       6,218.5         I cont of materials consumed       27,995.1       27,287.4       26,348.8       1,07,367.6         (b) Purchase of stock-in-trade       6,361.8       8,238.9       7,859.5       28,871.1         (c) Changes in inventories of finished goods, stock-in-trade and work-in-progress       (d) Employee benefits expense       11,626.4       11,315.5       10,263.2       44,756.2         (e) Employee benefits expense       1,1626.4       11,315.5       10,263.2       44,756.2         (b) Purchase of stock-in-trade       -       488.3       142.8       226.5         (g) Depreciation, amortisation and impairment expense       4,444.3       4,185.3	
(a) Net sales/ income from operations       83,811.2       78,931.5       74,919.2       3,13,781.3         (b) Other operating income       10.0       853.7       882.3       3,456.0         Total revenue from operations       83,821.2       79,785.2       75,801.5       3,17,237.3         2       Other income       116.0       -       -       -         (a) Foreign exchange gain (net)       116.0       -       -       -         (b) Others       1,232.1       1,572.9       1,356.2       6,218.5         Total income (1+2)       13,348.1       1,572.9       1,356.2       6,218.5         Total income (1+2)       1,348.1       1,572.9       1,356.2       6,218.5         3       Expenses       -       -       -       -         (c) Cost of materials consumed       27,995.1       27,287.4       26,348.8       1,07,367.6         (b) Purchase of stock-in-trade       6,361.8       8,238.9       7,859.5       28,871.1         (c) Changes in inventories of finished goods, stock-in-trade and (78.1)       (2,372.2)       (3,599.5)       (5,976.3)         work-in-progress       11,626.4       11,315.5       10,263.2       44,756.2         (e) Emance costs       1,150.2       1,1	
(b) Other operating income         10.0         853.7         882.3         3,456.0           Total revenue from operations         83,821.2         79,785.2         75,801.5         3,17,237.3           2         Other income         116.0         -         -           (a) Foreign exchange gain (net)         116.0         -         -           (b) Others         1,232.1         1,572.9         1,356.2         6,218.5           Total other income         1,348.1         1,572.9         1,356.2         6,218.5           Total income (1+2)         85,169.3         81,358.1         77,157.7         3,23,455.8           3         Expenses         -         -         -         -           (a) Cost of materials consumed         27,995.1         27,287.4         26,348.8         1,07,367.6           (b) Purchase of stock-in-trade         6,361.8         8,238.9         7,859.5         28,871.1           (c) Changes in inventories of finished goods, stock-in-trade and (78.1)         (2,372.2)         (3,599.5)         (5,976.3)           work-in-progress         11,626.4         11,315.5         10,263.2         44,756.2           (d) Employee benefits expense         1,466.4         4,185.3         3,543.3         16,494.2	
Total revenue from operations       83,821.2       79,785.2       75,801.5       3,17,237.3         Other income       116.0       -       -       -         (a) Foreign exchange gain (net)       116.0       -       -       -         (b) Others       1,232.1       1,572.9       1,356.2       6,218.5         Total other income       1,348.1       1,572.9       1,356.2       6,218.5         Total income (1+2)       85,169.3       81,358.1       77,157.7       3,23,455.8         4       Foreign exchange of stock-in-trade       6,361.8       8,238.9       7,859.5       28,871.1         (c) Changes in inventories of finished goods, stock-in-trade and work-in-progress       (2,072.2)       (3,599.5)       (2,5976.3)         (d) Employee benefits expense       11,626.4       11,315.5       10,263.2       44,756.2         (d) Employee benefits expense       11,150.2       1,184.8       894.3       4,572.4         (f) Foreign exchange loss (net)       -       498.3       142.8       226.5         (g) Depreciation, amortisation and impairment expense       19,996.8       19,037.5       18,058.6       76,164.3         Total expenses       71,496.5       69,375.5       63,511.0       2,72,476.0	
(a) Foreign exchange gain (net)       116.0       -       -         (b) Others       1,232.1       1,572.9       1,356.2       6,218.5         Total income (1+2)       85,169.3       81,358.1       77,157.7       3,23,455.8         3       Expenses       -       -       -       -         (a) Cost of materials consumed       27,995.1       27,287.4       26,348.8       1,07,367.6         (b) Purchase of stock-in-trade       6,361.8       8,238.9       7,859.5       28,871.1         (c) Changes in inventories of finished goods, stock-in-trade and (78.1)       (2,372.2)       (3,599.5)       (5,976.3)         work-in-progress       -       -       498.3       142.8       226.5         (d) Employee benefits expense       11,150.2       1,184.8       894.3       4,572.4         (f) Foreign exchange loss (net)       -       -       498.3       142.8       226.5         (g) Depreciation, amortisation and impairment expense       14,444.3       4,185.3       3,543.3       16,494.2         (h) Other expenses       19,996.8       19,037.5       63,511.0       2,72,476.0         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       11,982.6       13,646.7       50,979	
(b) Others       1,232.1       1,572.9       1,356.2       6,218.5         Total other income       1,348.1       1,572.9       1,356.2       6,218.5         Total income (1+2)       85,169.3       81,358.1       77,157.7       3,23,455.8         3       Expenses <ul> <li>(a) Cost of materials consumed</li> <li>(b) Purchase of stock-in-trade</li> <li>(c) Changes in inventories of finished goods, stock-in-trade and</li> <li>(c) Changes in inventories of finished goods, stock-in-trade and</li> <li>(d) Employee benefits expense</li> <li>(d) Employee benefits expense</li> <li>(e) Finance costs</li> <li>(f) Foreign exchange loss (net)</li> <li>(g) Depreciation, amortisation and impairment expense</li> <li>(h) Other expenses</li> <li>(h) Other expense</li> <li>(h) Other expense</li> <li>(h) Other expense</li> <li>(h) Other expense</li></ul>	
Total other income       1,348.1       1,572.9       1,356.2       6,218.5         Total income (1+2)       85,169.3       81,358.1       77,157.7       3,23,455.8         3       Expenses <ul> <li>(a) Cost of materials consumed</li> <li>(b) Purchase of stock-in-trade</li> <li>(c) Changes in inventories of finished goods, stock-in-trade and</li> <li>(c) Changes in inventories of finished goods, stock-in-trade and</li> <li>(78.1)</li> <li>(2,372.2)</li> <li>(3,599.5)</li> <li>(5,976.3)</li> <li>(a) Employee benefits expense</li> <li>(b) Purchase loss (net)</li> <li>(c) Finance costs</li> <li>(d) Employee benefits expense</li> <li>(e) Finance costs</li> <li>(f) Foreign exchange loss (net)</li> <li>(g) Depreciation, amortisation and impairment expense</li> <li>(h) Other expenses</li> <li>(h) Other expense</li> <li>(h) Other expenses</li></ul>	
Total income (1+2)       85,169.3       81,358.1       77,157.7       3,23,455.8         Image: Second Se	
3       Expenses <ul> <li>(a) Cost of materials consumed</li> <li>(b) Purchase of stock-in-trade</li> <li>(c) Changes in inventories of finished goods, stock-in-trade and</li> <li>(c) Changes in inventories of finished goods, stock-in-trade and</li> <li>(c) Changes in inventories of finished goods, stock-in-trade and</li> <li>(c) Changes in inventories of finished goods, stock-in-trade and</li> <li>(c) Changes in inventories of finished goods, stock-in-trade and</li> <li>(c) Changes in inventories of finished goods, stock-in-trade and</li> <li>(c) Changes in inventories of finished goods, stock-in-trade and</li> <li>(d) Employee benefits expense</li> <li>(d) Employee benefits expense</li> <li>(e) Finance costs</li> <li>(f) Foreign exchange loss (net)</li> <li>(e) Finance costs</li> <li>(f) Foreign exchange loss (net)</li> <li>(g) Depreciation, amortisation and impairment expense</li> <li>(h) Other expenses</li> <li>19,996.8</li> <li>19,037.5</li> <li>18,058.6</li> <li>76,164.3</li> <li>71,496.5</li> <li>69,375.5</li> <li>63,511.0</li> <li>2,72,476.0</li> </ul> 4     Profit before share of (loss)/profit of associates and joint ventures, net of tax <li>(a) Profit before exceptional items and tax (1+2-3)</li> 13,672.8         11,982.6         13,646.7 <li>50,979.8</li> 5         Share of profit/(loss) of associates and joint ventures, net of tax         (321.9)         15.9         (126.6)         (316.9)	
(a) Cost of materials consumed       27,995.1       27,287.4       26,348.8       1,07,367.6         (b) Purchase of stock-in-trade       6,361.8       8,238.9       7,859.5       28,871.1         (c) Changes in inventories of finished goods, stock-in-trade and work-in-progress       (2,372.2)       (3,599.5)       (5,976.3)         (d) Employee benefits expense       11,626.4       11,315.5       10,263.2       44,756.2         (e) Finance costs       1,1,50.2       1,184.8       894.3       4,572.4         (f) Foreign exchange loss (net)       -       498.3       142.8       226.5         (g) Depreciation, amortisation and impairment expense       4,444.3       4,185.3       3,543.3       16,494.2         (h) Other expenses       19,996.8       19,037.5       18,058.6       76,164.3         Total expenses       71,496.5       69,375.5       63,511.0       2,72,476.0         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       11,982.6       13,646.7       50,979.8         6       Profit before exceptional items and tax (1+2-3)       13,672.8       11,982.6       13,646.7       50,979.8         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       15.9       (126.6)       (3	
(a) Cost of materials consumed       27,995.1       27,287.4       26,348.8       1,07,367.6         (b) Purchase of stock-in-trade       6,361.8       8,238.9       7,859.5       28,871.1         (c) Changes in inventories of finished goods, stock-in-trade and work-in-progress       (2,372.2)       (3,599.5)       (5,976.3)         (d) Employee benefits expense       11,626.4       11,315.5       10,263.2       44,756.2         (e) Finance costs       1,1,50.2       1,184.8       894.3       4,572.4         (f) Foreign exchange loss (net)       -       498.3       142.8       226.5         (g) Depreciation, amortisation and impairment expense       4,444.3       4,185.3       3,543.3       16,494.2         (h) Other expenses       19,996.8       19,037.5       18,058.6       76,164.3         Total expenses       71,496.5       69,375.5       63,511.0       2,72,476.0         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       11,982.6       13,646.7       50,979.8         6       Profit before exceptional items and tax (1+2-3)       13,650.9       11,998.5       13,520.1       50,662.9         7       Fxceptional items (efer note 4)       -       -       -       -       1,221.1       - </td	
(b) Purchase of stock-in-trade       6,361.8       8,238.9       7,859.5       28,871.1         (c) Changes in inventories of finished goods, stock-in-trade and       (78.1)       (2,372.2)       (3,599.5)       (5,976.3)         work-in-progress       (d) Employee benefits expense       11,626.4       11,315.5       10,263.2       44,756.2         (e) Finance costs       1,150.2       1,184.8       894.3       4,572.4         (f) Foreign exchange loss (net)       -       498.3       142.8       226.5         (g) Depreciation, amortisation and impairment expense       4,444.3       4,185.3       3,543.3       16,494.2         (h) Other expenses       19,996.8       19,037.5       18,058.6       76,164.3         Total expenses       71,496.5       69,375.5       63,511.0       2,72,476.0         4       Profit before share of (loss)/profit of associates and joint ventures, exceptional items and tax (1+2-3)       13,672.8       11,982.6       13,646.7       50,979.8         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       15.9       (126.6)       (316.9)         6       Profit before exceptional items and tax (4+5)       13,350.9       11,998.5       13,520.1       50,662.9         7       Exceptional items (refer note 4) </td	
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress       (78.1)       (2,372.2)       (3,599.5)       (5,976.3)         work-in-progress       (d) Employee benefits expense       11,626.4       11,315.5       10,263.2       44,756.2         (e) Finance costs       1,150.2       1,184.8       894.3       4,572.4         (f) Foreign exchange loss (net)       -       498.3       142.8       226.5         (g) Depreciation, amortisation and impairment expense       4,444.3       4,185.3       3,543.3       16,494.2         (h) Other expenses       19,996.8       19,037.5       18,058.6       76,164.3         Total expenses       71,496.5       69,375.5       63,511.0       2,72,476.0         4       Profit before share of (loss)/profit of associates and joint ventures, exceptional items and tax (1+2-3)       13,672.8       11,982.6       13,646.7       50,979.8         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       15.9       (126.6)       (316.9)         7       Exceptional items and tax (4+5)       13,350.9       11,998.5       13,520.1       50,662.9         7       Exceptional items (refer note 4)       -       -       1,221.1       -         8       Profit before tax (6-7)	
work-in-progress       11,626.4       11,315.5       10,263.2       44,756.2         (d) Employee benefits expense       11,50.2       1,184.8       894.3       4,572.4         (e) Finance costs       1,150.2       1,184.8       894.3       4,572.4         (f) Foreign exchange loss (net)       -       498.3       142.8       226.5         (g) Depreciation, amortisation and impairment expense       4,444.3       4,185.3       3,543.3       16,494.2         (h) Other expenses       19,996.8       19,037.5       18,058.6       76,164.3         Total expenses       71,496.5       69,375.5       63,511.0       2,72,476.0         4       Profit before share of (loss)/profit of associates and joint ventures, exceptional items and tax (1+2-3)       11,982.6       13,646.7       50,979.8         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       15.9       (126.6)       (316.9)         7       Exceptional items and tax (4+5)       13,350.9       11,998.5       13,520.1       50,662.9         7       Fxceptional items (refer note 4)       -       -       1,221.1       -         8       Profit before tax (6-7)       13,350.9       11,998.5       12,299.0       50,662.9         9	
(d) Employee benefits expense       11,626.4       11,315.5       10,263.2       44,756.2         (e) Finance costs       1,150.2       1,184.8       894.3       4,572.4         (f) Foreign exchange loss (net)       498.3       142.8       226.5         (g) Depreciation, amortisation and impairment expense       4,444.3       4,185.3       3,543.3       16,494.2         (h) Other expenses       19,996.8       19,037.5       18,058.6       76,164.3         Total expenses       71,496.5       69,375.5       63,511.0       2,72,476.0         4       Profit before share of (loss)/profit of associates and joint ventures, exceptional items and tax (1+2-3)       11,982.6       13,646.7       50,979.8         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       15.9       (126.6)       (316.9)         7       Exceptional items and tax (1+2-3)       13,350.9       11,998.5       13,520.1       50,662.9         7       Exceptional items (refer note 4)       13,350.9       11,998.5       12,299.0       50,662.9         9       Totit before tax (6-7)       13,350.9       11,998.5       12,299.0       50,662.9	
(e) Finance costs       1,150.2       1,184.8       894.3       4,572.4         (f) Foreign exchange loss (net)       -       498.3       142.8       226.5         (g) Depreciation, amortisation and impairment expense       4,444.3       4,185.3       3,543.3       16,494.2         (h) Other expenses       19,996.8       19,037.5       18,058.6       76,164.3         Total expenses       71,496.5       69,375.5       63,511.0       2,72,476.0         4       Profit before share of (loss)/profit of associates and joint ventures, exceptional items and tax (1+2-3)       13,672.8       11,982.6       13,646.7       50,979.8         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       15.9       (126.6)       (316.9)         6       Profit before exceptional items and tax (4+5)       13,350.9       11,998.5       13,520.1       50,662.9         7       Fxceptional items (refer note 4)       -       -       1,221.1       -         8       Profit before tax (6-7)       13,350.9       11,998.5       12,299.0       50,662.9         9       Tax expense       -       -       -       50,662.9       50,662.9	
(f) Foreign exchange loss (net)       498.3       142.8       226.5         (g) Depreciation, amortisation and impairment expense       4,444.3       4,185.3       3,543.3       16,494.2         (h) Other expenses       19,996.8       19,037.5       18,058.6       76,164.3         Total expenses       71,496.5       69,375.5       63,511.0       2,72,476.0         4       Profit before share of (loss)/profit of associates and joint ventures, exceptional items and tax (1+2-3)       13,672.8       11,982.6       13,646.7       50,979.8         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       15.9       (126.6)       (316.9)         6       Profit before exceptional items and tax (4+5)       13,350.9       11,998.5       13,520.1       50,662.9         7       Exceptional items (refer note 4)       13,350.9       11,998.5       12,299.0       50,662.9         9       Tax expense       13,350.9       11,998.5       12,299.0       50,662.9	
(g) Depreciation, amortisation and impairment expense       4,444.3       4,185.3       3,543.3       16,494.2         (h) Other expenses       19,996.8       19,037.5       18,058.6       76,164.3         Total expenses       71,496.5       69,375.5       63,511.0       2,72,476.0         4       Profit before share of (loss)/profit of associates and joint ventures, exceptional items and tax (1+2-3)       11,982.6       13,646.7       50,979.8         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       15.9       (126.6)       (316.9)         6       Profit before exceptional items and tax (4+5)       13,350.9       11,988.5       13,520.1       50,662.9         7       Fxceptional items (refer note 4)       13,350.9       11,998.5       12,299.0       50,662.9         9       Tax expense       13,350.9       11,998.5       12,299.0       50,662.9	
(h) Other expenses       19,996.8       19,037.5       18,058.6       76,164.3         Total expenses       71,496.5       69,375.5       63,511.0       2,72,476.0         4       Profit before share of (loss)/profit of associates and joint ventures, exceptional items and tax (1+2-3)       13,672.8       11,982.6       13,646.7       50,979.8         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       15.9       (126.6)       (316.9)         6       Profit before exceptional items and tax (4+5)       13,350.9       11,998.5       13,520.1       50,662.9         7       Exceptional items (refer note 4)       -       -       1,221.1       -         8       Profit before tax (6-7)       13,350.9       11,998.5       12,299.0       50,662.9         9       Tax expense       -       -       -       -       -       -	
4       Profit before share of (loss)/profit of associates and joint ventures, exceptional items and tax (1+2-3)       13,672.8       11,982.6       13,646.7       50,979.8         5       Share of profit/(loss) of associates and joint ventures, net of tax       (321.9)       15.9       (126.6)       (316.9)         6       Profit before exceptional items and tax (4+5)       13,350.9       11,998.5       13,520.1       50,662.9         7       Exceptional items (refer note 4)       1,221.1       1,221.1       1,221.1         8       Profit before tax (6-7)       13,350.9       11,998.5       12,299.0       50,662.9         9       Tax expense       12,299.0       50,662.9       13,350.9       11,998.5       12,299.0	
exceptional items and tax (1+2-3)         (321.9)         15.9         (126.6)         (316.9)           5         Share of profit/(loss) of associates and joint ventures, net of tax         (321.9)         15.9         (126.6)         (316.9)           6         Profit before exceptional items and tax (4+5)         13,350.9         11,998.5         13,520.1         50,662.9           7         Exceptional items (refer note 4)         -         -         1,221.1         -           8         Profit before tax (6-7)         13,350.9         11,998.5         12,299.0         50,662.9           9         Tax expense         -         -         -         -         -	
exceptional items and tax (1+2-3)         (321.9)         15.9         (126.6)         (316.9)           5         Share of profit/(loss) of associates and joint ventures, net of tax         (321.9)         15.9         (126.6)         (316.9)           6         Profit before exceptional items and tax (4+5)         13,350.9         11,998.5         13,520.1         50,662.9           7         Exceptional items (refer note 4)         -         -         1,221.1         -           8         Profit before tax (6-7)         13,350.9         11,998.5         12,299.0         50,662.9           9         Tax expense         -         -         -         -         -	
5         Share of profit/(loss) of associates and joint ventures, net of tax         (321.9)         15.9         (126.6)         (316.9)           6         Profit before exceptional items and tax (4+5)         13,350.9         11,998.5         13,520.1         50,662.9           7         Exceptional items (refer note 4)         -         1,221.1         -           8         Profit before tax (6-7)         13,350.9         11,998.5         12,299.0         50,662.9           9         Tax expense         -         -         -         -         -	
6       Profit before exceptional items and tax (4+5)       13,350.9       11,998.5       13,520.1       50,662.9         7       Exceptional items (refer note 4)       -       1,221.1       -         8       Profit before tax (6-7)       13,350.9       11,998.5       12,299.0       50,662.9         9       Tax expense       -       -       -       -       -       -	
7     Exceptional items (refer note 4)     -     1,221.1       8     Profit before tax (6-7)     13,350.9     11,998.5     12,299.0       9     Tax expense     11,998.5     12,299.0	
8 Profit before tax (6-7) 13,350.9 11,998.5 12,299.0 50,662.9 Tax expense	
9 Tax expense	
Current tax         4,305.1         4,980.7         5,706.4         16,999.8           Deferred tax         17.5         (1,437.9)         (2,480.9)         (1.172.6)	
Total tax expense         4,322.6         3,542.8         3,225.5         15,827.2           0 Profit after tax (8-9)         9,028.3         8,455.7         9,073.5         34,835.7	
1 Other comprehensive Income	
A) Items that will not be reclassified subsequently to profit or	
loss:	
i) Re-measurement of defined employee benefit liability (83.0) (30.2) (125.0) (190.2)	
ii) Equity investments through other comprehensive income – 48.3 9.7 13.7 105.9	
net change in fair value	
iii) Income-tax relating to items that will not be reclassified to 6.0 5.6 19.4 21.1	
profit or loss	
B) Items that will be reclassified subsequently to profit or loss:	
i) Exchange differences on translating the financial statements 1,425.3 (637.8) (1,013.8) 3,099.4	
of foreign operations	
ii) Income-tax on items that will be reclassified subsequently to	
profit or loss	
Total other comprehensive income/(loss) (net of tax)         1,396.6         (652.7)         (1,105.7)         3,036.2	
Total other comprehensive income/(loss) (net of tax)         1,396.6         (652.7)         (1,105.7)         3,036.2           2 Total comprehensive income (net of tax) (10+11)         10,424.9         7,803.0         7,967.8         37,871.9	
Total other comprehensive income/(loss) (net of tax)         1,396.6         (652.7)         (1,105.7)         3,036.2           2 Total comprehensive income (net of tax) (10+11)         10,424.9         7,803.0         7,967.8         37,871.9           Attributable to:         10,424.9 <t< td=""></t<>	
Total other comprehensive income/(loss) (net of tax)         1,396.6         (652.7)         (1,105.7)         3,036.2           2         Total comprehensive income (net of tax) (10+11)         10,424.9         7,803.0         7,967.8         37,871.9           Attributable to:         0wners of the Parent Company         10,431.4         7,805.4         7,981.8         37,895.1	
Total other comprehensive income/(loss) (net of tax)         1,396.6         (652.7)         (1,105.7)         3,036.2           2         Total comprehensive income (net of tax) (10+11)         10,424.9         7,803.0         7,967.8         37,871.9           Attributable to:         0wners of the Parent Company         10,431.4         7,805.4         7,981.8         37,895.1           Non-controlling interest         (6.5)         (2.4)         (14.0)         (23.2)	
Total other comprehensive income/(loss) (net of tax)         1,396.6         (652.7)         (1,105.7)         3,036.2           2         Total comprehensive income (net of tax) (10+11)         10,424.9         7,803.0         7,967.8         37,871.9           Attributable to:         0wners of the Parent Company         10,431.4         7,805.4         7,981.8         37,895.1           Non-controlling interest         (6.5)         (2.4)         (14.0)         (23.2)           Out of total comprehensive income above,	
Total other comprehensive income/(loss) (net of tax)1,396.6(652.7)(1,105.7)3,036.22Total comprehensive income (net of tax) (10+11)10,424.97,803.07,967.837,871.9Attributable to:010,431.47,805.47,981.837,895.1Owners of the Parent Company10,431.47,805.47,981.837,895.1Non-controlling interest(6.5)(2.4)(14.0)(23.2)Out of total comprehensive income above, Profit after tax attributable to:	
Total other comprehensive income/(loss) (net of tax)         1,396.6         (652.7)         (1,105.7)         3,036.2           2         Total comprehensive income (net of tax) (10+11)         10,424.9         7,803.0         7,967.8         37,871.9           Attributable to:         0wners of the Parent Company         10,431.4         7,805.4         7,981.8         37,895.1           Non-controlling interest         (6.5)         (2.4)         (14.0)         (23.2)           Out of total comprehensive income above,	
Total other comprehensive income/(loss) (net of tax)         1,396.6         (652.7)         (1,105.7)         3,036.2           2 Total comprehensive income (net of tax) (10+11)         10,424.9         7,803.0         7,967.8         37,871.9           Attributable to:         0wners of the Parent Company         10,431.4         7,805.4         7,981.8         37,895.1           Non-controlling interest         (6.5)         (2.4)         (14.0)         (23.2)           Out of total comprehensive income above,	
Total other comprehensive income/(loss) (net of tax)         1,396.6         (652.7)         (1,105.7)         3,036.2           2 Total comprehensive income (net of tax) (10+11)         10,424.9         7,803.0         7,967.8         37,871.9           Attributable to:         0wners of the Parent Company         10,431.4         7,805.4         7,981.8         37,895.1           Non-controlling interest         (6.5)         (2.4)         (14.0)         (23.2)           Out of total comprehensive income above,	
Total other comprehensive income/(loss) (net of tax)1,396.6(652.7)(1,105.7)3,036.22Total comprehensive income (net of tax) (10+11)10,424.97,803.07,967.837,871.9Attributable to:0wners of the Parent Company10,431.47,805.47,981.837,895.1Non-controlling interest(6.5)(2.4)(14.0)(23.2)Out of total comprehensive income above,9,034.78,458.19,087.534,858.8Non-controlling interest(6.4)(2.4)(14.0)(23.1)Owners of the Parent Company9,034.78,458.19,087.534,858.8Non-controlling interest(6.4)(2.4)(14.0)(23.1)Other comprehensive income/(loss) attributable to:0000Owners of the Parent Company1,396.7(652.7)(1,105.7)3,036.3	
Total other comprehensive income/(loss) (net of tax)         1,396.6         (652.7)         (1,105.7)         3,036.2           12         Total comprehensive income (net of tax) (10+11)         10,424.9         7,803.0         7,967.8         37,871.9           Attributable to:         0         10,431.4         7,805.4         7,981.8         37,895.1           Non-controlling interest         (6.5)         (2.4)         (14.0)         (23.2)           Out of total comprehensive income above,         -         -         -         -           Profit after tax attributable to:         0         -         -         -           Owners of the Parent Company         9,034.7         8,458.1         9,087.5         34,858.8           Non-controlling interest         (6.4)         (2.4)         (14.0)         (23.1)           Other comprehensive income/(loss) attributable to:         -         -         -         -           Owners of the Parent Company         1,396.7         (652.7)         (1,105.7)         3,036.3           Non-controlling interest         (0.1)         -         -         (0.1)	
Total other comprehensive income/(loss) (net of tax)       1,396.6       (652.7)       (1,105.7)       3,036.2         12       Total comprehensive income (net of tax) (10+11)       10,424.9       7,803.0       7,967.8       37,871.9         Attributable to:       0wners of the Parent Company       10,431.4       7,805.4       7,981.8       37,895.1         Non-controlling interest       (6.5)       (2.4)       (14.0)       (23.2)         Out of total comprehensive income above,	
Total other comprehensive income/(loss) (net of tax)       1,396.6       (652.7)       (1,105.7)       3,036.2         12       Total comprehensive income (net of tax) (10+11)       10,424.9       7,803.0       7,967.8       37,871.9         Attributable to:       0wners of the Parent Company       10,431.4       7,805.4       7,981.8       37,895.1         Non-controlling interest       (6.5)       (2.4)       (14.0)       (23.2)         Out of total comprehensive income above,       9,034.7       8,458.1       9,087.5       34,858.8         Non-controlling interest       (6.4)       (2.4)       (14.0)       (23.1)         Other comprehensive income/(loss) attributable to:       0       1,396.7       (652.7)       (1,105.7)       3,036.2         Owners of the Parent Company       9,034.7       8,458.1       9,087.5       34,858.8       0         Non-controlling interest       (6.4)       (2.4)       (14.0)       (23.1)       (23.1)         Other comprehensive income/(loss) attributable to:       0       0       1,396.7       (652.7)       (1,105.7)       3,036.3         Non-controlling interest       (0.1)       =       (0.1)       (0.1)       (0.1)       (0.1)       (0.1)       (0.1)       (0.1)       3,25,952.4	
Total other comprehensive income/(loss) (net of tax)       1,396.6       (652.7)       (1,105.7)       3,036.2         12       Total comprehensive income (net of tax) (10+11)       10,424.9       7,803.0       7,967.8       37,871.9         Attributable to:       0wners of the Parent Company       10,431.4       7,805.4       7,981.8       37,895.1         Non-controlling interest       (6.5)       (2.4)       (14.0)       (23.2)         Out of total comprehensive income above,	



K .--- 4



(All amounts are in ₹ million,	unless otherwise stated
--------------------------------	-------------------------

5.         Asta         Asta         Asta         Asta           Non-         Particulars         Julia 2023         Julia 2024         Julia 2024           Asserts         Audited         Audited         Audited           Asserts         Sector         Julia 2024         Julia 2024         Julia 2024           Asserts         Asserts         Julia 2024         Julia 2024         Julia 2024           Asserts         Julia 2024         Julia 2024         Julia 2024         Julia 2024           Asserts         Julia 2024         Julia 2024         Julia 2024         Julia 2024           Property, Julia 2024         Julia 2024         Julia 2024         Julia 2024         Julia 2024           Control manufactorial events         Julia 2024         Julia 2024         Julia 2024         Julia 2024           Property, Julia 2024         Julia 2024         Julia 2024         Julia 2024         Julia 2024           Control manufactorial events         Julia 2024         Julia 2024         Julia 2024         Julia 2024           Interventions         Julia 2024         Julia 2024         Julia 2024         Julia 2024         Julia 2024           Interventions         Julia 2024         Julia 2024         Julia 2024         Julia 202	(All amounts are in ₹ million, unless oth			
ASSITS Audited Networks (11,19,9502 1,12,608,12,7333,12,733,12	SI.	Particulare	As at	As at
ASST 5         Assert 5         1,11,6,950.2         1,12,608.3           Netrocurrent assets         3,240.0         2,233.3           Intercurrent assets         3,240.0         2,233.3           Intercurrent assets         3,240.0         2,233.3           Intercurrent assets         3,240.0         2,233.3           Intercurrent assets         3,240.0         2,233.3           Investment accounted for using the equity method         5,533.6         1,233.3           Investment accounted for using the equity method         6,54         9,273.5           Investment accounted for using the equity method         5,537.1         3,500.0           Investment accounted for using the equity method         5,537.1         2,350.0           Other financial assets         1,05,437.2         2,202.6           I corrent assets         2,202.6         1,05,437.2         2,202.6           I corrent assets         0,01         555.8         1,05,437.2         2,08,02.3           I macho current assets         0,01         555.8         1,25,427.2         2,07,22.2           I current assets         0,01         555.8         1,25,427.2         2,07,22.2           I current assets         0,01         555.8         1,25,427.2         2,27,732.2 <td>No.</td> <td>Particulars</td> <td></td> <td>the second se</td>	No.	Particulars		the second se
1Non-urent assetsI.1.2.005.3Property phat and equipment1.2.2005.3Right of use sorts3.2.600Right of use sorts3.2.601Goadwill6.3.02Other intrapble assets under development1.2.3.0.13Intrapble assets under development1.2.3.0.13Intrapble assets under development4.5.6.1Intrapble assets under development4.5.6.1Intra-trail assets of for using the equip method4.5.6.1Intra-trail assets7.64.6Intra-trail assets7.64.6Intra-trail assets1.3.8.7.1Intra-trail assets1.3.8.7.1<			Audited	Audited
Property, plant and equipament         11,8,950.2         11,1,2,608.3           Capital work, merpagies         32,660.0         27,933.3           Right-of-use assets         6,160.2         3,555.0           Other intangible assets         10,393.4         2,553.13           Intangible assets         10,393.4         11,293.33           Investments accounted for using the equity method         455.4         99.78           Intangible assets         2,061.5         2,58.71           Intangible assets         10,033.2         -           Other financial assets         10,032.2         -           Other financial assets         10,054.72         9,008.23           Intandib assets         10,054.72         9,062.3           Intandib assets         10,054.72         9,008.23		ASSETS		
Capital work-m-progres         32,660.0         27,233.5           Right-of-use series         2,944.1         3,866.4           Goodwill         6,130.2         5,551.5           Other intrapple assets         19,877.4         23,551.5           Intrapple assets         19,877.4         23,551.5           Investment accounted for using the equity method         455.4         577.8           Investments         2,061.6         2,768.7           Investments         2,061.6         2,768.7           Other innon-current assets         3,877.1         3,510.0           Other innon-current assets         2,262.5         2,2936.5           Other innon-current assets         2,263.2         2,2936.5           Total non-current assets         2,263.2         2,2936.5           Investments         2,263.2         2,2936.5           Investments         2,263.2         2,2936.5           Total non-current assets         2,263.2         2,2936.5           Total non-current assets         2,263.2         2,263.2           Investments         2,263.2         2,2936.5         3,334.8           Investments         2,263.2         2,263.2         2,263.2           Investments         2,265.2	1	Non-current assets		
Right of use assts         2,944.1         2,246.2           Good will be assts         6,130.2         5,551.5           Other intangble assts under development         15,335.4         2,352.13           Investments accounted for using the equity method         45.4         947.8           Investments         2,061.6         2,288.7           Investments         1,033.3            Investments         3,377.3         3,510.0           Investments         3,377.3         3,510.0           Other innoutia assts         1,033.2            Trade receivables         3,377.3         3,510.0           Other innouria assts         2,286.25         1,20.8           Trade receivables         2,286.25         2,393.4           Investments         2,08.652.8         2,393.4           Investments         3,05.4         2,286.25           Investments         2,266.25         2,393.4           Bank balances other than cash and cash equivalents         2,266.25         2,393.4           Investments         2,267.25         2,235.4         2,286.25           Investments         2,266.25         2,393.4         2,356.2         2,356.2           Investments         2,266.25 </td <td></td> <td>Property, plant and equipment</td> <td>1,18,950.2</td> <td>1,12,608.3</td>		Property, plant and equipment	1,18,950.2	1,12,608.3
Goodwill         Cancel         5,551.5           Other inangble assts         19,877.4         23,521.3           Intangble assts         19,877.4         23,521.3           Intangble assts         19,877.4         23,521.3           Investments accounted for using the equity method         455.4         907.8           Investments accounted for using the equity method         455.4         907.8           Interstments accounted for using the equity method         67.4         2,88.3           Other innancial assets         1,003.2         -           Other innancial assets         1,003.2         -           Other innancial assets         1,003.2         -           Other innancial assets         2,036.2         1,21,216.2         2,229.6           Other innancial assets         1,005,497.2         9,008.23         -           Investments         1,05,497.2         9,008.23         -           Investments         1,05,497.2         9,008.23         -           Investments         2,056.2         2,048.4         -           Investments         2,056.2         2,048.4         -           Investments         2,057.1         -         -           Investments         2,057.0		Capital work-in-progress	32,660.0	27,393.9
Other intangble assets under development         19,887.4         25,921.3           Intrangble assets under development         16,339.4         11,233.3           Investments accounted for using the equity method         455.4         97.8           Investments         2,061.6         2,7.86.7           Loans         67.4         58.3           Trade receivables         1,033.2         -           Other financial assets         1,037.2         -           Other financial assets (net)         2,27.25.8         7.30.50.00           Onter rend ta savets (net)         2,395.8         -           Other financial assets         2,27.25.8         2.00(6.58.4           Other financial assets         1,05,497.2         98,082.3           Investments         1,05,497.2         98,082.3           Investments         2,27.25.8         2.00(6.58.5           Investments         2,26,25.3         4.30.93.8           Investments         2,26,26.2         2,88.8		Right-of-use assets	2,944.1	2,846.8
Intragible assets under development         11,233           Investments         2,661.6           Loars         6,74           Investments         2,661.6           Loars         6,74           Trade receivables         1,63,3           Other financial assets         1,052,3           Deferred tax assets (net)         1,223,5           Deferred tax assets (net)         2,262,25,1           Deferred tax assets         2,335,2           Total non-current assets         2,335,2           Deferred tax assets         1,05,437,2           Pinancial assets         1,05,437,2           Investments         1,05,437,2           Pinancial assets         1,05,437,2           Investments         2,662,5           Investments         1,05,437,2           Pinancial assets         1,05,437,2           Investments         2,662,5           Deferred tax equivalents         2,664,54           Sast bassets         1,05,437,2           Sast bassets         1,05,437,2           Sast bassets         2,015,03           Trade crecivables         2,71,02,4           Sast bassets         2,71,02,4           Total carrent assets         2,71,02,4 </td <td></td> <td></td> <td>6,180.2</td> <td>5,951.5</td>			6,180.2	5,951.5
Investments accounted for using the equity method455.4547.8Financial assets2,061.62,288.7Tade receivables6,7.4558.3Tade receivables1,063.2-Other financial assets5,37.7.13,510.0Deferred tar assets (net)4,37.63,832.9Other non-current assets2,262.5.12,006.58.8Tade receivables1,05,437.298.082.3Financial assets2,262.5.12,006.58.8Investments0.1505.8Tade receivables5,56.953,394.8Investments0.1505.8Tade receivables55.6.95.51,28.6Ucarret assets0.1505.8Investments0.1505.8Tade receivables2,27.2.22,665.4Other financial assets25.62,8.88.2.3Loans1,28.62,61.9.22,37.1.3Jassets held for sale2,7.1.2.2.4.62,3.7.1.37.1.3Total current assets2,7.1.2.2.4.62,3.7.1.37.1.3Jassets held for sale2,7.1.2.2.4.62,3.7.1.37.1.3Total Assets file 1.3.04,57.2.4.62,3.7.1.37.1.3Jasset held for sale2,7.1.2.2.4.62,3.7.1.37.1.3I current assets2,2.1.2.2.4.6.2.3.7.1.37.1.33,26.46.3.2.9.2.3.2.1.3Jasset held for sale3,26.46.3.2.9.2.3.2.1.3Loans1,4.5.4.3.2.2.7.2.2.2.3.2.4.33,2.5.6.5.5Other financial assets3,26.46.3.2.9.2.3.2.1.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3			19,867.4	23,521.3
Financial assets         2,061.6         2,268.7           Loars         1,063.2         -           Other financial assets         1,063.2         -           Other financial assets         1,252.66         1,21,254.           Non-current assets         2,393.5         2,299.6           Other non-current assets         2,393.5         2,299.67           Total non-current assets         1,05.487.2         98,082.31           Financial assets         1,05.487.2         98,082.31           Investments         1,05.487.2         98,082.31           Total non-current assets         2,35.58.3         33.93.48           Bank bianes other than cash and cash equivalents         2,35.58.4         2,37.79.2           Loars         2,75.42.46         2,37.79.2         2,56.43           Total current assets         2,75.24.2         2,75.42.46         2,87.59.7           Total current assets         2,75.52.4         2,77.92.7         2,55.64.3 </td <td></td> <td></td> <td></td> <td></td>				
Investments2,061.62,263.7Loars67.458.3Trade receivables1,063.2Other financial assets5,377.1Joss4,370.83,82.2Other non-current assets2,26.2Joss2,098.5Zorrent assets2,26.2Joss2,098.5Investories1,05,437.2Plancial assets2,26.2Investories1,05,437.2Stancial assets1,05,437.2Investories5,05.8Joss3,394.8Bank balances other than cash and cash equivalents55.6Loars22,542.8Loars2,27.2Other financial assets12.25Loars2,26.25Uher financial assets2,26.25Unvestories12.25Investories2,26.25Investories2,26.25Investories2,26.25Investories2,26.25Unvestories2,25.25Investories2,25.25Investories2,25.25Investories2,27.2Investories2,27.2Investories2,27.2Investories2,27.2Investories2,25.25Unvestories2,25.25Unvestories2,25.25Investories2,25.25Investories2,25.25Investories2,25.25Investories2,25.25Investories2,25.25Investories2,25.25Investories2,25.25Investories			455.4	947.8
Loas				
Tade receivables         1,08:2		Seed and a provide set of the set		
Other financial assets         5,377.1         3,510.0           Deferred tax assets (net)         1,292.6         3,832.5           Other non-current assets         2,285.5         2,293.6           Total non-current assets         2,26,255.1         2,06,658.8           Investnois         1,05,437.2         98,08.2.3           Financial assets         0.1         505.8           Investnois         5,7,593.3         48,107.4           Cash and cash equivalents         26,665.4         28,88.8           Dark halances other than cash and cash equivalents         26,665.4         28,88.8           Loarnet assets         27,712.4         25,061.3           Other financial assets         2,712.42.4         2,77.93.2           Other financial assets         2,712.42.4         2,77.93.2           Other financial assets         2,77.93.2         2,53.64.3           Other financial assets         2,77.93.2         2,53.64.3           Other current assets         2,77.93.2         2,53.74.3           Investnere assets         2,77.93.2         2,53.74.3           Other financial assets         2,77.93.2         2,53.64.3           Investnere assets         2,77.93.2         2,53.79.3           Investnere assets				58.3
Deferred tax assets (net)         12,295         12,126.4           Non-current assets         2,385         2,299           Other non-current assets         2,385.2         2,298,58           Immetrofies         1,05,437.2         98,08,0.3           Financial assets         0.1         505.8           Investments         57,459.3         449,167.4           Gash and cash equivalents         26,665.4         2,665.4           Jost and cash equivalents         26,665.4         2,665.4           Jost Assets         1,55.6         2,74.53           Jost Assets (net)         2,74.52.5         3,994.4           Jost Assets (net)         2,74.62.4         2,71,72.5           Jost Assets (net)         2,74.62.4         2,71,72.4           Current tax assets (net)         2,74.62.4         2,71,72.2           Jost Assets (net)         2,74.62.4         2,71,72.2           Jost Assets (net)         3,75.02         2,77.62.4           Jost Assets (net)         3,75.02         2,77.62.4           Jost Assets (net)         3,77.02         2,77.62.4           Jost Assets (net)         3,77.02         2,77.62.4           Jost Assets (net)         3,77.02         2,77.62.4 <td< td=""><td></td><td>The second se</td><td></td><td>2 510 0</td></td<>		The second se		2 510 0
Non-current tax sates (net)         1,370,8         1,370,8         1,370,8         2,293,6           Total non-current assets         2,208,658,8         2,209,658,8         2,209,658,8           Investroits         1,05,437,2         98,082,3         1,05,437,2         98,082,3           Investroits         0,1         505,8         35,248,3         36,167,4           Cash and cash equivalents         26,665,4         28,88,2         33,934,4           Bank balances other than cash and cash equivalents         26,665,4         28,88,2         33,934,8           Loans         2,71,624,6         2,83,70,2         25,664,3         2,84,8,2           Loans         2,71,624,6         2,37,102,2         2,56,43         2,37,102,2         2,56,43           Other current assets         2,27,1624,6         2,37,712,2         2,56,43         2,37,712,2         2,56,43           Total current assets         2,37,712,2         2,56,43         2,37,712,2         2,56,43         2,71,624,6         2,37,712,2         2,56,43         2,37,712,2         2,56,43         2,37,712,2         2,56,43         2,37,712,2         2,56,43         2,37,712,2         2,57,02,13         2,57,02,13,13         2,57,02,13,13         2,55,64,33,2,2,25,70,03,2,15,13         2,55,55,9,02,13,13,13         2				
Other non-current assets         2.938.5         2.293.6           2         Current assets         2.06,558.8           2         Current assets         1,05,437.2         9,008.23           1         Investments         0.1         505.8           1         Trada non-current assets         0.1         505.8           1         Trada receivables         55,699.5         33,934.8           2         Cash and cash equivalents         55,699.5         33,934.8           1         Cash and cash equivalents         2,666.5         2,894.8           1         Cash and cash equivalents         2,666.5         2,894.8           1         Current tax assets (net)         2,71.8         5.6.7           2         Jassets held for sale         -4.337.17.9.2         -4.337.17.9.2           3         Assets held for sale         -4.337.17.9.2         -4.337.17.9.2           2         Jassets held for sale         -4.337.17.9.2         -4.337.19.2           2         Jassets held for sale         -2.37.19.2.1         -2.37.9.2.1           2         Jassets held for sale         -2.39.2.1         -2.39.2.1           2         Jassets held for sale         -2.39.2.1         -2.39.2.1			· · ·	
Total non-current assets         2.26,253.1         2.26,858.8           2         Current assets         1,05,437.2         98,082.3           Inventories         0.01         505.8           Inventories         57,459.3         48,167.4           Cash and cash equivalents         55,689.5         33,934.8           Bank balances other than cash and cash equivalents         26,665.4         28,88.2           Loars         26,665.4         28,88.2           Current tassets         22,570.2         25,364.3           Total current assets         22,37.12         -           Current tasset         22,27.122.42         23,83.23           Total current assets         22,37.12         -           Current tasset         22,29.22.22         2,37.12           Total current assets         22,29.82.80.2         2,29.82.80		Other non-current assets		
Investments         1,05,437.2         98,082.3           Financial assets         0.1         505.8           Trade receivables         57,459.3         48,167.4           Cash and cash equivalents         55,669.5         33,94.8           Bank balances ofther than cash and cash equivalents         25,665.4         28,848.2           Loans         26,665.4         28,848.2           Other financial assets         26,657.4         28,848.2           Current tassets         22,570.2         -25,364.3           Total current assets         22,75.246.2         23,77.19.2           Assets held for sale         -         4,307.1           Total current assets         22,76.824.2         2,97.824.2           Statis that for sale         -         4,307.1           Total current assets         22,56.38.2         2.29,82.2           Equity share capital         32,552.4         2.97,824.2           Statis thubutable to owners of the Parent Company         3,25,53.2         2.29,82.08.0           Total equity         3,26,649.3         2,98.08.0           Ulabilities         3,20,27.3         3,25,55.5           Other encurrent liabilities         2,32,92.1         2,52.53.2           Borrowings         2,38.25		Total non-current assets	2,26,225.1	
Incentories         1,05,437.2         98,082.3           Financial assets         0.1         505.8           Trade receivables         55,69.3         33,934.8           Bank balances other than cash and cash equivalents         25,665.4         28,862.3           Loans         26,665.4         28,862.3           Other financial assets         26,665.4         28,862.3           Loans         26,665.4         28,862.3           Other financial assets         26,657.4         28,745.3           Current tassets         22,702.2         -25,364.3           Total current assets         27,562.46         23,771.92           Assets held for sale         -         4,307.15           Total current assets         27,562.46         23,771.92           Assets held for sale         -         4,307.15           Equity Asset capital         32,555.8         585.9           Other capital         32,555.82         2.97,842.3           Isolitities         32,555.8         2,98,508.0           Total equity         32,555.83         2,98,508.0           Total equity         32,555.8         2,98,508.0           Isolitities         114.00         114.00           Borrowings	2	Current assets		
Financial assets         0.1         505.8           Investments         57,459.3         48,157.4           Cash and cash equivalents         25,669.3         33,934.8           Bank balances other than cash and cash equivalents         26,65.4         28,848.2           Loans         7,459.3         48,157.4           Other financial assets         2,613.1         27,85.7           Chart and for sale         2,37,79.2         2,25,64.3           Other current assets         2,71,624.6         2,37,79.2           Assets held for sale         -         4,337.1           TOTAL ASSETS (1+2+3)         4,97,849.7         4,50.715.1           EQUITY AND LIABILITIES         -         4,337.3           Cautr and the capital         560.8         585.9           Chart assets         2,07,823.2         2,98,428.2           Courrent assets         -         4,337.3           Cautra asset for sale         -         6(3.9)         90.0           Catal cautra         3,26,459.3         2,98,508.0         -           Cautra tabilities         -         -         2,32,95.08.0           Cautra tabilities         -         -         -           Barrowings         15,616.5		Production of the above of the second se	1,05,437.2	98.082.3
Tade receivables         57,453         48,157.4           Cash and cash equivalents         55,683.5         33,93.4           Bark balances other than cash and cash equivalents         26,665.4         28,848.2           Loans         155.6         128.6           Other financial assets         2,75.65.1         22,651.1           Current tax assets (net)         27,862.4         23,702.2         25,364.3           Total current assets         2,77,4624.6         2,37,719.2         4,337.1           Total current assets         2,37,482.0         4,37,248.9         4,37,248.9           Curry AND LABILITIES         2,497.849.7         4,50,715.1         4,37,248.9         4,32,595.2         2,37,832.1         2,39,800.0           Non-controlling interest         3,26,463.3         2,39,500.0         3,32,64,63.3         2,39,500.0         1,32,64,63.3         2,39,500.0         1,32,64,63.3         2,2,52,53.3		Financial assets	-,,	
Cash and cash equivalents         55,693         33,932,8           Bank balances other than cash and cash equivalents         26,665,4         28,848,2           Loans         128,6         128,6           Other financial assets         2,619,5         2,631,1           Current tassets         2,71,624,6         2,37,719,2           Total current assets         2,71,624,6         2,37,719,2           Assets held for sale         -         4,337,1           Total current assets         2,71,624,6         2,37,719,2           Assets held for sale         -         4,337,1           Total current assets         2,71,624,6         2,37,719,2           Assets held for sale         -         4,337,1           Total current assets         2,77,822,1         2,97,842,1           Equity Attributable to owners of the Parent Company         3,26,533,2         2,99,824,80           Other equity         3,26,533,2         2,99,820,80,0           Labilities         2,98,928,00         3,26,469,3         2,99,508,0           Labilities         2,29,224,20,428,0         3,26,469,3         2,99,508,0           Labilities         2,29,428,0         3,26,469,3         2,99,508,0           Labilitities         2,39,508,0		Investments	0.1	505.8
Bank balances other than cash and cash equivalents         22,665.4         22,645.2           Loans         155.6         128.6           Other financial assets         24,552.2         2,615.5         2,253.64.3           Current tax assets (net)         22,570.2         22,53.64.3         23,570.2         22,53.64.3           Total current assets         27,1624.6         2,37,71.9         4,337.1           Total current assets         2,71,624.6         2,37,71.9         4,337.1           TotAL ASSETS (14:24)         4,50.715.1         4,337.1           EQUITY AND LIABILITIES         580.8         585.9           Cuity stare capital         3,25,552.4         2,97,842.1           Cuity attributable to owners of the Parent Company         3,26,649.3         2,98,508.0           Non-courtolling interest         (63.9)         80.0         63.9         80.0           Valiabilities         3,32,64.69.3         2,98,508.0         13,561.5         21,349.0           Utabilities         3,22,57.2         2,98,508.0         13,561.5         21,349.0           Von-courtor liabilities         15,616.5         21,349.0         3,25,57.3         2,98,508.0           Valiabilities (net)         3,32,77         3,325,55.5         2,57.0 <td< td=""><td></td><td>Trade receivables</td><td>57,459.3</td><td>48,167.4</td></td<>		Trade receivables	57,459.3	48,167.4
Leans135.6128.6Other financial assets (net)2,619.52,631.1Current tax assets (net)27.856.7Other current assets2,71,624.62,37,719.23Assets held for sale-4,337.1Total current assets2,78,29.24,50,715.14,97,89.74,50,715.14,97,89.74,000 the activation of the Parent Company3,26,533.22,97,842.1Attributable to owners of the Parent Company3,26,533.22,98,48.0Non-controlling interest3,26,469.32,295.52.4Non-controlling interest2,295.22,295.25.2Non-controlling interest2,295.22,295.25.2Non-controlling interest2,295.22,295.25.2Non-controlling interest2,295.22,295.25.2Non-controlling interest2,295.22,255.2Non-controlling interest2,295.22,255.2Non-controlling interest2,302.13,302.7Assets allabilities2,322.73,302.7Non-current liabilities3,322.73,302.7Non-current liabilities24,557.030,215.8Current tabilities24,557.030,215.8Total on-current liabilities63,800.341,803.2Borrowings63,800.341,803.2Lease liabilities24,557.030,215.8Total outstanding dues of micro enterprises and small enterprises862.3791.5Total outstanding dues of cellors other than micro enterprises and small enterprises41,026.243,756.79 <td></td> <td>Cash and cash equivalents</td> <td>55,689.5</td> <td>33,934.8</td>		Cash and cash equivalents	55,689.5	33,934.8
Other financial assets2,619.52,63.1.1Current tax assets (net)23,570.225,364.3Total current assets2,71,624.62,37,71.9.2Assets held for sale-4,337.1TOTAL ASSETS [1+2+3)4,97,849.74,50,715.1EQUITY AND LIABILITIES4,97,849.74,50,715.1EQUITY AND LIABILITIES3,26,533.22,97,842.1EQUITY AND CLABLITIESEquity3,26,533.22,98,428.0Chore equity3,26,649.32,98,508.0Equity share capitalNon-controlling interestIsabilitiesNon-controlling interestNon-controlling interestNon-controlling interestProvisions2,829.32,257.03,02.27.3ProvisionsBorrowingsIcase liabilities (net)Total non-current liabilitiesBorrowingsIcase liabilities (net)<			26,665.4	28,848.2
Current tax assets (net)         27.8         5.6.7           Other current assets         23,570.2         25,364.3           Total current assets         27.16,24.6         2.3,71.12           3         Assets held for sale         -         4,337.1           TOTAL ASSETS (1+2+3)         4,97,849.7         4,50.715.1           EQUITY AND UABILITIES         4,97,849.7         4,50.715.1           Equity share capital         580.8         585.9           Other equity         3,26,533.2         2,98,428.0           Coursent liabilities         (63.9)         80.0           Total equity         3,26,469.3         2,98,508.0           Liabilities         -         4,93,25.9           Non-controlling interest         (63.9)         80.0           Total equity         3,26,469.3         2,98,508.0           Liabilities         -         -         -           Financial liabilities (net)         -         -         -           Others         -         -         -         -           Financial liabilities (net)         -         -         -         -           Others         -         -         -         -           Total ono-current liabi				
Other current assets         23,570.2         25,364.3           Total current assets         2,71,624.6         2,37,152.4         2,37,152.4           A ssets held for sale         -         -         4,337.1           TOTAL ASSETS (1+2+3)         4,97,849.7         4,50,715.1           EQUITY AND LABILITIES         -         -         -           Equity         580.8         585.9           Other equity         3,25,935.2         2,98,428.0           Non-controlling interest         -         -           Non-controlling interest         -         -           Borrowings         15,616.5         21,349.0           Lease Habilities         -         -           Financial liabilities (net)         -         -           Deferred tax liabilities (net)         -         -           Other on-current liabilities         -         -           Borrowings         -         -         -           Lease Habilities (net)         -         -         -           Other on-current liabilities (net)         -         -         -           Deferred tax liabilities (net)         -         -         -           Other on-current liabilities         -		in strand wear strategie find the		
Total current assets         2,71,624.6         2,37,719.2           3 Assets held for sale         -         4,337.1           TOTAL ASSETS (1+2+3)         4,97,849.7         4,50,715.1           EQUITY AND LIABILITIES         3,25,533.2         2,50,715.1           Equity share capital         3,25,533.2         2,98,428.0           Other equity         3,26,533.2         2,98,428.0           Equity stributable to owners of the Parent Company         3,26,533.2         2,98,428.0           Non-controlling interest         (63.3)         80.0           Total equity         3,26,69.3         2,98,508.0           Liabilities         -         15,616.5         21,349.0           Non-current liabilities         -         134.0         154.2           Provisions         2,252.5         3,25,70         3,25,65.0           Other non-current liabilities (net)         -         3,365.6         -           Other non-current liabilities         -         -         3,46.7           Total equipables         -         -         3,26.4.7           Current liabilities (net)         -         -         -           Borrowings         -         -         -         3,26.7           Current liab				120-046234
3     Assets held for sale     -     4,337,1       TOTAL ASSETS (1+2+3)     4,97,849.7     4,50,715.1       EQUITY AND LABILITIES     3,25,952.4     2,97,842.1       Equity     3,25,952.4     2,97,842.1       Equity stare capital     3,26,533.2     2,98,428.0       Other equity     3,26,533.2     2,98,428.0       Non-controlling interest     0(63.9)     80.0       Total equity     3,26,469.3     2,98,508.0       Liabilities     3,26,469.3     2,98,508.0       Iabilities     3,26,469.3     2,98,508.0       Values liabilities     2,302.1     2,525.3       Other equity     2,322.1     2,525.3       Other on-current liabilities     2,302.1     2,525.3       Other on-current liabilities     3,032.7     3,565.6       Other non-current liabilities     3,032.7     3,565.6       Other non-current liabilities     3,032.7     3,565.6       Other non-current liabilities     545.4     364.7       Total on-current liabilities     63,800.3     41,803.2       Borrowings     63,800.3     41,803.2       Lease liabilities     819.8     798.8       Trade payables     613,000.3     41,803.2       total outstanding dues of micro enterprises and small enterprises     63,800.3				
TOTAL ASSETS (1+2+3)4.50,715.1EQUITY AND LIABILITIES4.97,849,74.50,715.1Equity Stare capital3.85.95.85.9Other equity3.25,952.42.97,842.1Equity stare capital3.25,952.42.97,842.1Other equity3.26,633.22.98,608.0I bailities3.26,649.32.98,508.0I bailities3.26,649.32.98,508.0I bailities15,616.52.1,349.0I bailities1.5,616.52.1,349.0I case liabilities2.829.32,257.0Othere on-current liabilities (net)3.023.73.365.6Othere no-current liabilities5.95.42.4557.0Provisions2.4557.03.0,215.8Current liabilities5.95.83.97.8Financial liabilities5.95.63.03.21Othere no-current liabilities5.95.63.03.27.0Deferred tax liabilities (net)2.4557.03.0,215.8Current liabilities5.95.63.03.21.5.8Financial liabilities63.800.341.803.2Lease liabilities63.80.341.803.2Lease liabilities5.95.83.97.8Total non-current liabilities5.96.83.97.8Trade payables63.80.341.803.2Lease liabilities5.96.83.97.8Total outstanding dues of reditors other than micro enterprises and small enterprises41.02.2Other current liabilities5.96.88.77.3Provisions5.96.838.77.3Other current liabili	2		2,/1,624.6	
EQUITY AND LIABILITIESEquity Equity Attributable to owners of the Parent Company3,26,533.2Other equity Equity attributable to owners of the Parent Company3,26,533.2Other equity Equity attributable to owners of the Parent Company3,26,633.2Non-controlling interest(63.9)Total equity3,26,469.3Libbilities3,26,469.3Non-current liabilities15,616.5Provisions2,392.1Others3,303.7Others3,303.7Others3,303.7Other on-current liabilities556.6Other no-current liabilities545.4Stailities24,557.0Other no-current liabilities545.4Financial liabilities24,557.030,21.73,032.74,042.41,4,032.4<	3			
IEquity Equity share capital580.8585.9CollColl580.8585.9CollColl3,25,552.42,97,842.1Equity attributable to owners of the Parent Company3,26,533.22,98,428.0Non-controlling interest(63.9)80.0Total equity3,26,649.32,98,508.0Liabilities3,26,649.32,98,508.0Provisions15,616.521,349.0Lease liabilities (net)2,392.12,525.3Other equity2,829.32,257.0Deferred tax liabilities (net)2,829.32,277.0Deferred tax liabilities24,557.03,022.7Total non-current liabilities545.4364.7Total non-current liabilities24,557.03,215.8Current liabilities819.8798.8Trade payables63,800.341,803.2total outstanding dues of micro enterprises and small enterprises63,800.341,803.2Other financial liabilities29,241.621,015.9Other financial liabilities5468.38,773.8Provisions29,241.621,015.9Other financial liabilities5,468.38,773.8Provisions2,255.62,567.9Current liabilities5,468.38,773.8Provisions2,241.621,015.9Other current liabilities5,468.38,773.8Provisions2,255.62,567.9Current liabilities (net)2,249.012,490.1Trade payables5,468.38,773.		TOTAL ASSETS (1+2+3)	4,97,849.7	4,50,715.1
IEquity Equity share capital580.8585.9CollColl580.8585.9CollColl3,25,552.42,97,842.1Equity attributable to owners of the Parent Company3,26,533.22,98,428.0Non-controlling interest(63.9)80.0Total equity3,26,649.32,98,508.0Liabilities3,26,649.32,98,508.0Provisions15,616.521,349.0Lease liabilities (net)2,392.12,525.3Other equity2,829.32,257.0Deferred tax liabilities (net)2,829.32,277.0Deferred tax liabilities24,557.03,022.7Total non-current liabilities545.4364.7Total non-current liabilities24,557.03,215.8Current liabilities819.8798.8Trade payables63,800.341,803.2total outstanding dues of micro enterprises and small enterprises63,800.341,803.2Other financial liabilities29,241.621,015.9Other financial liabilities5468.38,773.8Provisions29,241.621,015.9Other financial liabilities5,468.38,773.8Provisions2,255.62,567.9Current liabilities5,468.38,773.8Provisions2,241.621,015.9Other current liabilities5,468.38,773.8Provisions2,255.62,567.9Current liabilities (net)2,249.012,490.1Trade payables5,468.38,773.				
Equity share capital580.8585.9Other equity3,25,952.42,97,842.1Equity attributable to owners of the Parent Company3,26,533.22,98,428.0Non-controlling interest(63.9)80.0Total equity3,26,469.32,98,508.0Labilities3,26,469.32,98,508.0Soncurrent liabilities15,616.521,349.0Borrowings15,616.521,349.0Lease liabilities2,392.12,525.3Others141.0154.2Provisions2,829.32,257.0Deferred tax liabilities (net)3,02.15.8Total non-current liabilities545.4364.7Total non-current liabilities545.4364.7Total non-current liabilities545.4364.7Total non-current liabilities819.8798.8Trade payables819.8798.8Trade payables862.3791.5total outstanding dues of micro enterprises and small enterprises862.3791.5Other runert liabilities29,241.621,015.9Other runert liabilities29,241.621,015.9Other runert liabilities29,241.621,015.9Other runert liabilities2,365.62,567.9Current liabilities2,480.32,490.1Total outstanding dues of creditors other than micro enterprises and small enterprises29,241.6Other functial liabilities29,241.621,015.9Other current liabilities (net)2,849.32,490.1Other tiabilities (net	1	DISC - ADDO CONTRACTOR DISCONDUCTION DISCONDUCTION		
Other equity3,25,952.42,97,942.1Equity attributable to owners of the Parent Company3,26,533.22,98,428.0Non-controlling interest3,26,489.32,98,508.0Idabilities3,26,489.32,98,508.0Vancurrent liabilities3,26,489.32,98,508.0Financial liabilities15,616.521,349.0Lease liabilities2,392.12,525.3Others141.0154.2Provisions2,257.02,492.1Deferred tax liabilities (net)3,032.73,565.6Other non-current liabilities545.4364.7Total oncurrent liabilities545.4364.7Stand liabilities819.8798.8Trade payables63,800.341,803.2Lease liabilities819.8798.8Trade payables10,026.243,750.1Other sing dues of micro enterprises and small enterprises29,241.621,015.9Other rurrent liabilities29,241.621,015.9Other rurrent liabilities2,257.022,57.525,57.8Trade payables862.3791.530,215.8Trade payables819.8798.8798.8Trade payables29,241.621,015.921,015.9Other rurrent liabilities29,241.621,015.9Other rurrent liabilities2,468.38,773.8Provisions2,468.38,773.8Provisions2,459.32,459.3Other rurrent liabilities (net)2,469.32,490.1Total current liabilities (	-		580.8	585.0
Equity attributable to owners of the Parent Company Non-controlling interest3,26,533.2 (63.9)2,98,428.0 (80.0)Total equity3,26,469.32,98,508.0Uabilities3,26,469.32,98,508.02Non-current liabilities15,616.521,349.0Borrowings2,392.12,525.3Others141.0154.2Provisions2,829.32,257.0Deferred tax liabilities3,032.73,565.6Other non-current liabilities3,032.73,565.6Total non-current liabilities3,032.73,565.6Other non-current liabilities24,557.030,215.8Current liabilities63,800.341,803.2Lease liabilities819.8798.3Total outstanding dues of micro enterprises and small enterprises41,026.243,750.1Other rinancial liabilities29,241.621,015.9Other current liabilities29,241.621,015.9Other rinancial liabilities29,241.621,015.9Other current liabilities29,241.621,015.9Other rinancial liabilities29,241.621,015.9Other current liabilities29,241.621,015.9Other standing dues of creditors other than micro enterprises and small enterprises2,265.3Other current liabilities2,567.92,267.9Current tax liabilities (net)2,269.32,2490.1Total current liabilities (net)2,269.32,490.1Total current liabilities (net)2,269.32,490.1Total current l				
Non-controlling interest(63.9)80.0Total equity3,26,469.32,98,508.0Labilities3,26,469.32,98,508.0Non-current liabilities11Borrowings15,616.521,349.0Lease liabilities2,992.12,525.3Others141.0154.2Provisions2,829.32,257.0Deferred tax liabilities (net)3,032.73,565.6Other non-current liabilities545.4364.7Total non-current liabilities24,557.030,215.83Current liabilities63,800.341,803.2Lease liabilities819.8798.8Trade payables862.3791.5total outstanding dues of micro enterprises and small enterprises41,026.243,750.1Other rourent liabilities29,241.621,015.9Other rourent liabilities24,453.32,755.6Other rourent liabilities (net)2,64				
LiabilitiesImage: constraint of the second seco		Non-controlling interest	and the second second	
2Non-current liabilitiesImage: constraint of the second sec		Total equity	3,26,469.3	2,98,508.0
Financial liabilitiesImage: Second Secon		Liabilities		
Borrowings15,616.521,349,0Lease liabilities2,392.12,525.3Others141.0154.2Provisions2,829.32,257.0Deferred tax liabilities (net)3,032.73,565.6Other non-current liabilities545.4364.7Total non-current liabilities24,557.030,215.8Borrowings63,800.341,803.2Lease liabilities819.8798.8Trade payables63,800.341,803.2Lotal outstanding dues of micro enterprises and small enterprises862.3791.5Other financial liabilities24,750.1791.5Other financial liabilities24,750.121,755.6Other financial liabilities24,750.121,215.9Other financial liabilities24,750.121,215.9Other financial liabilities24,750.121,215.9Other financial liabilities24,750.121,015.9Other financial liabilities24,750.121,015.9Other financial liabilities24,750.121,015.9Other financial liabilities24,750.121,015.9Other financial liabilities24,750.121,015.9Other financial liabilities24,750.121,015.9Other financial liabilities24,62.32,750.6Other financial liabilities2,657.92,755.6Other financial liabilities (net)2,849.32,490.1Total current liabilities (net)2,849.32,490.1Total current liabilities1,46,823.41,21,991.3 <td>2</td> <td>Non-current liabilities</td> <td>1</td> <td></td>	2	Non-current liabilities	1	
Lease liabilities2,392.12,525.3Others141.0154.2Provisions2,829.32,257.0Deferred tax liabilities (net)3,032.73,565.6Other non-current liabilities545.4364.7Total non-current liabilities24,557.030,215.83Current liabilities63,800.341,803.2Initial liabilities800.341,803.2819.8Financial liabilities819.8798.8Trade payables63,800.341,006.2total outstanding dues of micro enterprises and small enterprises862.3791.5total outstanding dues of creditors other than micro enterprises and small enterprises29,241.621,015.9Other current liabilities5,468.38,773.8Provisions29,755.62,567.92,755.62,567.9Current tax liabilities (net)2,849.32,490.12,849.32,490.1Total current liabilities1,46,823.41,21,991.31,46,823.41,21,991.3		Financial liabilities		
Others141.0154.2Provisions2,829.32,257.0Deferred tax liabilities (net)3,032.73,565.6Other non-current liabilities545.4364.7Total non-current liabilities24,557.030,215.8Current liabilities63,800.341,803.2Lease liabilities819.8798.8Trade payables63,800.341,803.2Lease liabilities819.8798.8Trade payables643,002.73,015.9Other rinancial liabilities862.3791.5Other financial liabilities29,241.621,015.9Other current liabilities5468.38,773.8Provisions5468.38,773.8Other current liabilities (net)2,849.32,490.1Total current liabilities (net)2,849.32,490.1Total current liabilities (net)1,46,823.41,21,991.3		-	15,616.5	21,349.0
Provisions2,829.32,257.0Deferred tax liabilities (net)3,032.73,565.6Other non-current liabilities545.4364.7Total non-current liabilities24,557.030,215.83Current liabilities63,800.341,803.2Borrowings63,800.341,803.2Lease liabilities819.8798.8Trade payables862.3791.5total outstanding dues of micro enterprises and small enterprises41,026.243,750.1Other financial liabilities29,241.621,015.9Other current liabilities5,468.38,773.8Provisions2,755.62,567.9Current tax liabilities (net)2,849.32,490.1Total current liabilities (net)1,46,823.41,21,991.3		144.97		
Deferred tax liabilities (net)3,032.73,565.6Other non-current liabilities545.4364.7Total non-current liabilities24,557.030,215.83Current liabilities63,800.341,803.2Financial liabilities819.8798.8Trade payables819.8798.8total outstanding dues of micro enterprises and small enterprises862.3791.5total outstanding dues of creditors other than micro enterprises and small enterprises862.3791.5Other financial liabilities29,241.621,015.9Other current liabilities5,468.38,773.8Provisions2,755.62,567.9Current tax liabilities (net)2,849.32,490.1Total current liabilities1,46,823.41,21,991.3				
Other non-current liabilities545.4364.7Total non-current liabilities24,557.030,215.83Current liabilities41,803.2Financial liabilities819.8798.8Borrowings63,800.341,803.2Lease liabilities819.8798.8Trade payables62.3791.5total outstanding dues of micro enterprises and small enterprises41,026.243,750.1Other financial liabilities29,241.621,015.9Other current liabilities5,468.38,773.8Provisions2,755.62,567.9Current tax liabilities (net)2,849.32,490.1Total current liabilities1,46,823.41,21,991.3		AND THE PERSON NO. THE PERSON NO. THE		
Total non-current liabilities24,557.030,215.83Current liabilities			Same and a second	
3Current liabilities Financial liabilities Borrowings Lease liabilities total outstanding dues of micro enterprises and small enterprises63,800.3 819.841,803.2 798.8 798.8Trade payables total outstanding dues of creditors other than micro enterprises and small enterprises862.3 41,026.2791.5 43,750.1Other financial liabilities Other current liabilities29,241.6 2,241.621,015.9 2,5468.38,773.8 8,773.8 2,755.6Provisions Current tax liabilities (net)2,849.3 2,490.12,490.1 1,21,991.3		Same and results with a second s		
Financial liabilities63,800.341,803.2Borrowings63,800.341,803.2Lease liabilities819.8798.8Trade payables791.5total outstanding dues of micro enterprises and small enterprises862.3791.5total outstanding dues of creditors other than micro enterprises and small enterprises41,026.243,750.1Other financial liabilities29,241.621,015.9Other current liabilities5,468.38,773.8Provisions2,755.62,567.9Current tax liabilities (net)2,849.32,490.1Total current liabilities1,46,823.41,21,991.3			24,557.0	50,215.8
Borrowings63,800.341,803.2Lease liabilities819.8798.8Trade payables11total outstanding dues of micro enterprises and small enterprises862.3791.5total outstanding dues of creditors other than micro enterprises and small enterprises41,026.243,750.1Other financial liabilities29,241.621,015.9Other current liabilities5,468.38,773.8Provisions2,755.62,567.9Current tax liabilities (net)2,849.32,490.1Total current liabilities1,46,823.41,21,991.3	3			
Lease liabilities819.8798.8Trade payablestotal outstanding dues of micro enterprises and small enterprises862.3791.5total outstanding dues of creditors other than micro enterprises and small enterprises41,026.243,750.1Other financial liabilities29,241.621,015.9Other current liabilities5,468.38,773.8Provisions2,755.62,567.9Current tax liabilities (net)2,849.32,490.1Total current liabilities1,46,823.41,21,991.3			63 800 2	41 902 2
Trade payables862.3total outstanding dues of micro enterprises and small enterprises862.3total outstanding dues of creditors other than micro enterprises and small enterprises41,026.2Other financial liabilities29,241.6Other current liabilities5,468.3Provisions2,755.6Current tax liabilities (net)2,849.3Total current liabilities1,46,823.41,21,991.3				
total outstanding dues of micro enterprises and small enterprises862.3791.5total outstanding dues of creditors other than micro enterprises and small enterprises41,026.243,750.1Other financial liabilities29,241.621,015.9Other current liabilities5,468.38,773.8Provisions2,755.62,567.9Current tax liabilities (net)2,849.32,490.1Total current liabilities1,46,823.41,21,991.3			010.0	750.0
total outstanding dues of creditors other than micro enterprises and small enterprises41,026.243,750.1Other financial liabilities29,241.621,015.9Other current liabilities5,468.38,773.8Provisions2,755.62,567.9Current tax liabilities (net)2,849.32,490.1Total current liabilities1,46,823.41,21,991.3			862.3	791 5
Other financial liabilities         29,241.6         21,015.9           Other current liabilities         5,468.3         8,773.8           Provisions         2,755.6         2,567.9           Current tax liabilities (net)         2,849.3         2,490.1           Total current liabilities         1,46,823.4         1,21,991.3				
Other current liabilities         5,468.3         8,773.8           Provisions         2,755.6         2,567.9           Current tax liabilities (net)         2,849.3         2,490.1           Total current liabilities         1,46,823.4         1,21,991.3				
Provisions         2,755.6         2,567.9           Current tax liabilities (net)         2,849.3         2,490.1           Total current liabilities         1,46,823.4         1,21,991.3		Other current liabilities	A 02.0	2.01
Current tax liabilities (net)         2,849.3         2,490.1           Total current liabilities         1,46,823.4         1,21,991.3		Provisions	and the second second second	Second second second
			2,849.3	
TOTAL EQUITY AND LIABILITIES (1+2+3) 4,50,715.1		Total current liabilities	1,46,823.4	1,21,991.3
		TOTAL EQUITY AND LIABILITIES (1+2+3)	4,97,849.7	4,50,715.1





SI.	(All amounts are in	₹ million, unless of	therwise stated)
		For the year	For the year
No.	De estimate a	ended	ended
	Particulars	31.03.2025	31.03.2024
		Audited	Audited
	FLOW FROM OPERATING ACTIVITIES		
	ofit before tax	50,662.9	43,799.9
	ments for :	20,002.12	10,70010
	preciation, amortisation and impairment expense	16,494.2	15,216.6
	wance for expected credit losses (net)	188.0	232.8
Liat	vilities no longer required written back	(121.4)	(100.5)
Inve	entories written off	9 1	66.8
Ma	rk-to-market gain on derivative financial instruments (net)	168.8	(27.0)
Unr	realised exchange loss/(gain) (net)	587.1	(511.4)
	s/(profit) on sale of property, plant and equipment (net)	89.4	(234.9)
1.	te-off of intangible assets under development (net)	114.2	326.2
	re of loss of associates and joint ventures	316.9	171.5
	fit on sale of investments	(367.0)	(1.0)
	ance costs	4,403.8	2,680.9
	erest income	(3,532.4)	(2,857.6)
	ting profit before working capital changes	69,004.5	58,762.3
	nents in working capital: rrease)/decrease in inventories	(7.254.0)	(42.026.0)
		(7,354.9)	(13,036.8)
	rrease)/decrease in trade receivables rrease)/decrease in other financial assets	(8,620.8)	(2,641.9)
	rease)/decrease in other infancial assets	(1,716.1) 1,712.7	(1,736.0) (6,689.7)
/ L	rease/(decrease) in trade payables	(3,108.9)	(6,689.7) 5,828.4
	rease/(decrease) in provision for employee benefits	(3,108.9) 589.9	5,828.4
	rease/(decrease) in other financial liabilities	9,368.3	3,174.1
	rease/(decrease) in other liabilities	(3,315.0)	(2,634.3)
	enerated from operating activities	56,559.7	42,011.6
	e taxes paid (net of refunds)	(17,313.5)	(17,666.4)
	sh generated from operating activities (A)	39,246.2	24,345.2
entra percenterative	FLOW FROM INVESTING ACTIVITIES		
	ase of property, plant and equipment, including movement in capital work- in- progress, capital	(19,678.6)	(27,803.3)
100	ces and capital creditors (net)		
	ase of intangible assets and intangible assets under development	(5,516.9)	(7,811.7)
	eds from sale of property, plant and equipment	28.4	602.8
	ase of controlling interest in subsidiaries	(113.9)	8
3. 2000 00 000 00	ase of non-current investments	(230.2)	(235.9)
	eds from sale of non-current investments eds from sale of current investments (net)	22.5	765,1
	nent in other bank balances	1,089.3	1,005.3
	st received	2,167.7	(11,890.2)
intere:	screceived	3,473.7	
Net ca	sh used in investing activities (B)		2,808.4
		(18,758.0)	(42,559.5)
3 CASH	FLOW FROM FINANCING ACTIVITIES	(18,758.0)	
	FLOW FROM FINANCING ACTIVITIES		
Buy ba	ack of equity shares (including tax and transaction cost)	(9,302.4)	(42,559.5)
Buy ba Procee	ack of equity shares (including tax and transaction cost) ads from non-current borrowings	(9,302.4) 6,614.3	(42,559.5)
Buy ba Procee Repay	ack of equity shares (including tax and transaction cost)	(9,302.4)	(42,559.5) 15,632.4 (171,7)
Buy ba Procee Repay	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings eds/(repayment) of current borrowings (net)	(9,302.4) 6,614.3 (11,188.6) 20,611.4	(42,559.5) 15,632.4 (171,7) (847.6)
Buy ba Procee Repay Procee Interes	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings eds/(repayment) of current borrowings (net)	(9,302.4) 6,614.3 (11,188.6)	(42,559.5) 15,632.4 (171,7)
Buy ba Procee Repay Procee Interes Repay	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings eds/(repayment) of current borrowings (net) st paid	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2)	(42,559.5) 15,632.4 (171,7) (847.6) (2,506.5)
Buy ba Procee Repay Procee Interes Repay Acquis	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings eds/(repayment) of current borrowings (net) st paid ment of lease liabilities	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3)	(42,559.5) 15,632.4 (171,7) (847.6) (2,506.5)
Buy ba Procee Repay Procee Interes Repay Acquis Mover	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings eds/(repayment) of current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4)	(42,559.5) 15,632.4 (171.7) (847.6) (2,506.5) (1,466.0) (2,636.4)
Buy ba Procee Repay Procee Interes Repay Acquis Mover	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings eds/(repayment) of current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0)	(42,559.5) 15,632.4 (171.7) (847.6) (2,506.5) (1,466.0)
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b>	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) eds/(repayment) of current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary nent in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C)	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8 21,686.0	(42,559.5) 15,632.4 (171.7) (847.6) (2,506.5) (1,466.0) (2,636.4)
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b> <b>Net in</b> Cash a	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) eds/(repayment) of current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C) nd cash equivalents at the beginning of the year	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8	(42,559.5) 15,632.4 (171.7) (847.6) (2,506.5) (1,466.0) (2,636.4) 8,004.2
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b> <b>Net in</b> Cash a Add: C	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) eds/(repayment) of current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C) nd cash equivalents at the beginning of the year cash and cash equivalents on acquisition of a subsidiary	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8 21,686.0 33,854.3 6.6	(42,559.5) 15,632.4 (171,7) (847.6) (2,506.5) (1,466.0) (2,636.4) 8,004.2 (10,210.1) 43,922.7
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b> <b>Net in</b> Cash a Add: C	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) eds/(repayment) of current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C) nd cash equivalents at the beginning of the year	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8 21,686.0 33,854.3	(42,559.5) 15,632.4 (171,7) (847.6) (2,506.5) (1,466.0) (2,636.4) 8,004.2 (10,210.1)
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b> <b>Net in</b> Cash a Add: C Effect	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C) nd cash equivalents at the beginning of the year iash and cash equivalents on acquisition of a subsidiary of exchange differences on cash and cash equivalents	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8 21,686.0 33,854.3 6.6 91.0	(42,559.5) 15,632.4 (171.7) (847.6) (2,506.5) (1,466.0) (2,636.4) 8,004.2 (10,210.1) 43,922.7 141.7
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b> <b>Net in</b> Cash a Add: C Effect	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C) nd cash equivalents at the beginning of the year iash and cash equivalents on acquisition of a subsidiary of exchange differences on cash and cash equivalents	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8 21,686.0 33,854.3 6.6	(42,559.5) 15,632.4 (171,7) (847.6) (2,506.5) (1,466.0) (2,636.4) 8,004.2 (10,210.1) 43,922.7
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b> <b>Net in</b> Cash a Add: C Effect	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) st gaid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C) nd cash equivalents at the beginning of the year iash and cash equivalents on acquisition of a subsidiary of exchange differences on cash and cash equivalents ind cash equivalents at the end of the year ind cash equivalents at the end of the year	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8 21,686.0 33,854.3 6.6 91.0 55,637.9	(42,559.5) 15,632.4 (171.7) (847.6) (2,506.5) (1,466.0) (2,636.4) 8,004.2 (10,210.1) 43,922.7 141.7 33,854.3
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b> <b>Net in</b> Cash a Add: C Effect <b>Cash a</b> Cash a	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) st gaid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C) nd cash equivalents at the beginning of the year cash and cash equivalents on acquisition of a subsidiary of exchange differences on cash and cash equivalents med cash equivalents at the end of the year cash equivalents at the end of the year med cash equivalents comprise of: in hand	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8 21,686.0 33,854.3 6.6 91.0	(42,559.5) 15,632.4 (171.7) (847.6) (2,506.5) (1,466.0) (2,636.4) 8,004.2 (10,210.1) 43,922.7 141.7
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b> <b>Net in</b> Cash a Add: C Effect <b>Cash a</b> Cash a Cash a	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C) nd cash equivalents at the beginning of the year iash and cash equivalents on acquisition of a subsidiary of exchange differences on cash and cash equivalents ind cash equivalents at the end of the year iash and cash equivalents at the end of the year ind cash equivalents comprise of: in hand is with banks	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8 21,686.0 33,8554.3 6.6 91.0 555,637.9 2.1	(42,559.5) 15,632.4 (171,7) (847.6) (2,506.5) (1,466.0) (2,636.4) 8,004.2 (10,210.1) 43,922.7 141.7 33,854.3 2.6
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b> <b>Net in</b> Cash a Add: C Effect <b>Cash a</b> Cash a Cash o Balanc - in cu	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C) nd cash equivalents at the beginning of the year iash and cash equivalents on acquisition of a subsidiary of exchange differences on cash and cash equivalents ind cash equivalents at the end of the year maching equivalents at the end of the year ment cash equivalents comprise of: n hand we with banks irrent account	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8 21,686.0 33,854.3 6.6 91.0 55,637.9 2.1 2.1	(42,559.5) 15,632.4 (171,7) (847.6) (2,506.5) (1,466.0) (2,636.4) 8,004.2 (10,210.1) 43,922.7 141.7 33,854.3 2.6 12,823.1
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b> <b>Net in</b> Cash a Add: C Effect <b>Cash a</b> Cash a Cash o Balance - in cu	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C) nd cash equivalents at the beginning of the year iash and cash equivalents on acquisition of a subsidiary of exchange differences on cash and cash equivalents ind cash equivalents at the end of the year ind cash equivalents at the end of the year ind cash equivalents comprise of: in hand is with banks irrent account oney market	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8 21,686.0 33,854.3 6.6 91.0 55,637.9 2.1 26,491.7 1,046.6	(42,559.5) 15,632.4 (171.7) (847.6) (2,506.5) (1,466.0) (2,636.4) 8,004.2 (10,210.1) 43,922.7 141.7 33,854.3 2.6 12,823.1 993.4
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b> <b>Net in</b> Cash a Add: C Effect <b>Cash a</b> Cash a Cash o Balanc - in cu - in m	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C) nd cash equivalents at the beginning of the year iash and cash equivalents on acquisition of a subsidiary of exchange differences on cash and cash equivalents ind cash equivalents at the end of the year ind cash equivalents at the end of the year ind cash equivalents comprise of: in hand is with banks irrent account oney market eposit account	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8 21,686.0 33,854.3 6.6 91.0 55,637.9 2.1 26,491.7 1,046.6 28,149.1	(42,559.5) 15,632.4 (171.7) (847.6) (2,506.5) (1,466.0) (2,636.4) 8,004.2 (10,210.1) 43,922.7 141.7 33,854.3 2.6 12,823.1 993.4 20,115.7
Buy ba Procee Repay Procee Interes Repay Acquis Mover <b>Net ca</b> <b>Net in</b> Cash a Add: C Effect <b>Cash a</b> Cash a Cash a Cash o Balanc - in cu	ack of equity shares (including tax and transaction cost) eds from non-current borrowings ment of non-current borrowings (net) st paid ment of lease liabilities ition of non-controlling interest in subsidiary ment in unclaimed dividend sh generated from financing activities (C) crease / (decrease) in cash and cash equivalents (A + B + C) nd cash equivalents at the beginning of the year iash and cash equivalents on acquisition of a subsidiary of exchange differences on cash and cash equivalents ind cash equivalents at the end of the year ind cash equivalents at the end of the year ind cash equivalents comprise of: in hand is with banks irrent account oney market	(9,302.4) 6,614.3 (11,188.6) 20,611.4 (4,203.2) (1,098.3) (225.0) (10.4) 1,197.8 21,686.0 33,854.3 6.6 91.0 55,637.9 2.1 26,491.7 1,046.6	(42,559.5) 15,632.4 (171,7) (847.6) (2,506.5) (1,466.0) (2,636.4) 8,004.2 (10,210.1) 43,922.7 141.7 33,854.3 2.6 12,823.1 993.4



к..<u>-Ц</u>



#### NOTES

- 1 The above consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above consolidated financial results has been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on May 26, 2025. The results for the year ended March 31, 2025 has been audited and for the guarter ended March 31, 2025 has been reviewed by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31, 2025 and have issued an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2025.
- 4 Exceptional items represent the following items which have been credited/(debited) to consolidated statement of profit and loss.

Particulars	the second second second second second		Quarter ended	Year ended	Year ended
	31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
Loss on restructuring of business (refer note i)		5	(289.1)	3	(986.6)
Gain on settlement with customer (refer note ii)			1,306.00	24 - L	1,306.0
Loss on write-off of non-current assets (refer note iii)	-	-	(2,238.0)		(2,238.0)
Total loss			(1,221,1)	*	(1,918.6)

Note:

i) Accrual of severance pay and certain demolition charges on account of restructuring of business of Auro PR Inc., a step-down subsidiary of the Company. ii) Gain arising on account of settlement of balances with a customer by Auro PR Inc., a step-down subsidiary of the Company.

iii) Loss arising on account of write-down of certain non-current assets held by Eugia US Manufacturing LLC, a step-down subsidiary of the Company, to its fair value less cost to sell, consequent to the sale of the assets.

5 The Group operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".

6 During the year ended March 31, 2025:

i. The Group acquired 520 equity shares (representing 52% stake) in Purple Bellflower (Pty) Limited, South Africa through its wholly owned subsidiary Aurogen South Africa (Pty) Limited. Consequent to the said acquisition, Purple Bellflower (Pty) Limited has become a wholly owned subsidiary of Aurogen South Africa (Pty) Limited.

ii. The Group acquired 500 equity shares (representing 100% stake) in Ace Laboratories Limited, UK through its wholly owned step-down subsidiary Agile Pharma BV.

iii. Aurex B.V. The Netherlands, merged with Aurobindo Pharma B.V. The Netherlands w.e.f. April 1, 2024.

iv. The Parent Company acquired 590,361 (representing 49% stake) in GLS Pharma Limited, India. Consequent to the said acquisition, GLS Pharma became a wholly owned subsidiary of Aurobindo Pharma Limited.

v., The Group divested 927,237 equity shares (representing 50% stake) in Novagen Pharma (PTY) Ltd and 245 equity shares (representing 24.50% stake) in Novagen BBBEE Invest Co. (PTY) Ltd, joint ventures through its wholly owned step down subsidiary Aurogen South Africa (PTY) Ltd. Consequently, the group has accounted gain on disposal of investmetn was other income.

vi. TheraNym Biologics Private Limited, a wholly owned subsidiary of the Company, has allotted 2,041 equity shares (representing 2% stake) to minority shareholders w.e.f. December 11, 2024. Post allotment, the TheraNym Biologics Private Limited ceased to be wholly-owned subsidiary.

7 The Board of Directors of the Parent company at their meeting held on July 18, 2024, approved buyback of 5,136,986 fully paid-up equity shares of face value of ₹ 1 each (representing 0.88% of the total number of equity share shares of the parent company) for an aggregate value not exceeding ₹ 7,500.0 million (buyback size) (excluding transaction cost and tax on buyback) at a maximum buyback price of ₹ 1,460/- per equity share. Upon completion of the buyback, the Parent company extinguished the equity shares in compliance with applicable rules and regulations. Consequently, the paid up equity share capital of the Parent company was reduced by ₹5.1 million. The aggregate amount paid for buyback was ₹9,302.4

million including tax and related expenses.

8 The figures for the current quarter and quarter ended March 31, 2024, are the balancing figures between the audited figures in respect of full financial year ended March 31, 2025 and March 31, 2024, respectively and published year to date figures up to third quarter ended December 31, 2024 and December 31, 2023, respectively, which were subject to limited review by the statutory auditors.

> By Order of the Board For Aurobindo Pharma Limited

K.Nithyananda Reddy

DIN-01284195



Place: Hyderabad Date : May 26, 2025



Chartered Accountants Meenakshi Pride Rock Tower III [Block – M], 8th & 9th floors Survey No. 23, Gachibowli Serilingampally Municipality Ranga Reddy District Hyderabad-500032 Telangana, India

# INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

## **Opinion and Conclusion**

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2025 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2025 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of audited consolidated financial results for the year ended March 31, 2025 and unaudited consolidated financial results for the quarter ended March 31, 2025" of **AUROBINDO PHARMA LIMITED** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group"), and its share of the net loss after tax and other comprehensive loss of its joint ventures and associates for the quarter and year ended March 31, 2025, (the "Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

## (a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements its subsidiaries and joint ventures referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2025:

- (i) includes the financial results of the subsidiaries, associates and joint ventures listed in Annexure I.
- (ii) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the year ended March 31, 2025.

### (b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2025

With respect to the Unaudited Consolidated Financial Results for the quarter ended March 31, 2025, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review reports of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Unaudited Consolidated Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

M

# Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group, its associates and joint ventures in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

## Management's and Board of Directors' Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2025, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2025 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including its associates and joint ventures in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

The respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its associates and joint ventures and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group, its associates and joint ventures are responsible for overseeing the financial reporting process of the Group, its associates and joint ventures.

## Auditor's Responsibilities

### (a) Audit of the Consolidated Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and joint ventures to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and joint ventures to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the entities within the Group and its associates and joint ventures to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## (b) Review of the Consolidated Financial Results for the quarter ended March 31, 2025

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

## **Other Matters**

We did not audit the financial statements of 70 subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of ₹ 369,226.0 million as at March 31, 2025 and total revenues of ₹ 60,201.1 million and ₹ 223,335.3 million the quarter and year ended March 31, 2025 respectively, total net profit after tax of ₹ 1,711.7 million and ₹ 8,630.3 million for the quarter and year ended March 31, 2025 respectively and total comprehensive income of ₹ 1,631.9 million and ₹ 8,538.5 million for the quarter and year ended March 31, 2025 respectively and net cash inflows of INR 16,159 million for the year ended March 31, 2025, as considered in the Statement. The consolidated financial results also include the Group's share of net loss after tax of ₹ 313.8 million and ₹ 317.4 million for the quarter and year ended March 31, 2025 respectively and total comprehensive loss of ₹ 313.7 million and ₹ 317.4 million for the guarter and year ended March 31, 2025 respectively, as considered in the Statement, in respect of 3 joint ventures whose financial statements have not been audited by us. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.

The consolidated financial results also include the Group's share of net (loss) / profit after tax of (₹ 8.1 million) and ₹ 0.5 million for the quarter and year ended March 31, 2025 respectively and total comprehensive (loss) / income of (₹ 8.1 million) and ₹ 0.5 million in respect of 2 associates, whose financial statements have not been audited by us. These financial statements are unaudited and have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these associates, is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial statements are not material to the Group.

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For DELOITTE HASKINS & SELLS

Chartered Accountants (Firm's Registration No. 008072S)

Non

C Manish Muralidhar Partner Membership No. 213649 UDIN: 25213649BMOENH8321

Place: Hyderabad Date: May 26, 2025

# Annexure I to the Independent Auditor's Report on Audit of Annual Consolidated Financial Results and review of Quarterly Financial results

S.No Name of Component Country Relationship Helix Healthcare B.V. The Netherlands **Direct Subsidiary** 1 Direct Subsidiary 2 APL Pharma Thai Limited Thailand Aurobindo Pharma Industria Farmaceutica Ltd 3 Brazil Direct Subsidiary Aurobindo Pharma Produtos Farmaceuticos Brazil **Direct Subsidiary** 4 Limitada 5 All Pharma (Shanghai) Trading Co Ltd China Direct Subsidiary 6 Aurobindo Pharma USA Inc. USA **Direct Subsidiary** Direct Subsidiary 7 APL Healthcare Limited India Direct Subsidiary Auro Peptides Ltd 8 India 9 Apitoria Pharma Private Limited Direct Subsidiary India 10 Auroactive Pharma Private Limited India Direct Subsidiary CuraTeQ Biologics Private Limited Direct Subsidiary 11 India AuroZest Private Limited India Direct Subsidiary 12 13 Aurobindo Antibiotics Private Limited India **Direct Subsidiary** 14 Eugia Pharma Specialities Ltd India Direct Subsidiary 15 GLS Pharma Private Limited India **Direct Subsidiary** TheraNyM Biologics Private Limited 16 India **Direct Subsidiary** Auro Trading Private Limited (w.e.f November India **Direct Subsidiary** 17 22, 2023) 18 Aurobindo Pharma Foundation India Direct Subsidiary Step-Down Subsidiary 19 Auro Vaccines Private Limited India 20 Agile Pharma B.V. The Netherlands Step-Down Subsidiary 21 Aurex B.V. (merged with Aurobindo Pharma The Netherlands Step-Down Subsidiary B.V. w.e.f. April 1, 2024) 22 United Kingdom Step-Down Subsidiary Milpharm Limited 23 Aurobindo Pharma (Malta) Ltd Step-Down Subsidiary Malta APL Swift Services (Malta) Ltd Step-Down Subsidiary 24 Malta Aurobindo Pharma (Romania) s.r.l Romania Step-Down Subsidiary 25 Step-Down Subsidiary 26 Pharmacin B.V. The Netherlands 27 Aurovitas Pharma Polska Poland Step-Down Subsidiary 28 Generis Farmaceutica S.A. Portugal Step-Down Subsidiary 29 Generis Phar, Unipessoal Lda Portugal Step-Down Subsidiary 30 Aurobindo Pharma (Italia) S.r.l Step-Down Subsidiary Italy 31 Arrow Generiques SAS Step-Down Subsidiary France 1980 Puren Pharma GmbH, Germany Step-Down Subsidiary 32 Germany 33 Puren Pharma GmbH & Co., KG Step-Down Subsidiary Germany 34 Aurovitas Spain SA Step-Down Subsidiary Spain 35 Aurobindo Pharma B.V. The Netherlands Step-Down Subsidiary Aurovitas Spol s.r.o **Czech Republic** Step-Down Subsidiary 36 37 Apotex Europe B.V. The Netherlands Step-Down Subsidiary 38 Aurovitas Nederland B.V The Netherlands Step-Down Subsidiary Step-Down Subsidiary 39 Sameko Farma B.V. The Netherlands Leidapharm B.V. Step-Down Subsidiary 40 The Netherlands Step-Down Subsidiary Marel B.V. 41 The Netherlands Pharma Dossier B.V. The Netherlands Step-Down Subsidiary 42 Aurobindo NV/SA Belgium Step-Down Subsidiary 43 Czech Republic Step-Down Subsidiary 44 CuraTeQ Biologics s.r.o. 45 Eugia Pharma B.V. The Netherlands Step-Down Subsidiary Step-Down Subsidiary 46 Eugia Pharma (Malta) Limited Malta Eugia (UK) Limited United Kingdom Step-Down Subsidiary 47

The annual consolidated financial results include results of the following entities:



S.No	Name of Component	Country	Relationship
48	Auro Pharma Inc.	Canada	Step-Down Subsidiary
49	Aurobindo Pharma (Pty) Ltd	South Africa	Step-Down Subsidiary
50	Aurobindo Pharma Japan KK	Japan	Step-Down Subsidiary
51	Aurovida Farmaceutica SA DE CV	Mexico	Step-Down Subsidiary
52	Aurobindo Pharma Colombia S.A.S	Colombia	Step-Down Subsidiary
53	Aurogen South Africa (PTY) Ltd	South Africa	Step-Down Subsidiary
54	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Step-Down Subsidiary
55	Aurovitas Pharma (Taizhou) Ltd	China	Step-Down Subsidiary
56	Aurobindo Pharma FZ-LLC	Dubai	Step-Down Subsidiary
57	Aurosalud SA De CV	Mexico	Step-Down Subsidiary
58	Auro PR Inc.	Puerto Rico	Step-Down Subsidiary
59	Eugia Pharma Inc.	Canada	Step-Down Subsidiary
60	Eugia Pharma (Australia) PTY Limited	Australia	Step-Down Subsidiary
61	Eugia Pharma Industria Farmaceutica Limitada	Brazil	Step-Down Subsidiary
62	Aurobindo Pharma Ukraine LLC	Ukraine	Step-Down Subsidiary
63	Eugia Pharma Colombia S.A.S.	Colombia	Step-Down Subsidiary
64	PT Aurogen Pharma	Indonesia	Step-Down Subsidiary
65	Aurolife Pharma LLC	USA	Step-Down Subsidiary
66	Auro Health LLC	USA	Step-Down Subsidiary
67	Auro AR LLC	USA	Step-Down Subsidiary
68	Auro Vaccines LLC	USA	Step-Down Subsidiary
69	AuroLogistics LLC	USA	Step-Down Subsidiary
70	Acrotech Biopharma Inc	USA	Step-Down Subsidiary
71	Auro Science LLC	USA	Step-Down Subsidiary
72	Auro Packaging LLC	USA	Step-Down Subsidiary
73	Vespyr Brands, LLC	USA	Step-Down Subsidiary
74	Eugia Inc.	USA	Step-Down Subsidiary
75	Eugia US LLC	USA	Step-Down Subsidiary
76	Eugia US Manufacturing LLC	USA	Step-Down Subsidiary
77	Eugia Steriles Private Limited	India	Step-Down Subsidiary
78	Lyfius Pharma Private Limited	India	Step-Down Subsidiary
79	Qule Pharma Private Limited	India	Step-Down Subsidiary
80	Eugia SEZ Private Limited	India	Step-Down Subsidiary
81	Auro Pharma LLC (w.e.f July 24, 2023)	Russia	Step-Down Subsidiary
82	Purple Bellflower, South Africa (w.e.f. April 30, 2024)	South Africa	Step-Down Subsidiary
83	Ace Laboratories Limited (w.e.f. June 28, 2024)	United Kingdom	Step-Down Subsidiary
84	Luoxin Aurovitas Pharm (Chengdu) Co. Ltd.	China	Joint venture
85	Raidurgam Developers Limited	India	Joint venture
86	Tergene Biotech Limited	India	Joint venture
87	Novagen Pharma (Pty) Ltd (upto October 1, 2024)	South Africa	Joint venture
88	Novagen BBBEE Invest Co (Pty) Ltd (upto October 1, 2024)	South Africa	Joint venture
89	NVNR (Ramannapet I) Power Plant Private Limited	India	Associate
90	NVNR (Ramannapet II) Power Plant Private Limited	India	Associate

1 W



Annexure

Sl No.	Particulars	Details	
1	Reason for Change viz. appointment	Appointment of MRR & Associates, Peer Reviewed Firm of Company Secretaries in Practice (Firm registration number: S2025TS1022400), as Secretarial Auditors of the Company.	
2	Date of appointment and term of appointment	The Board of Directors of the Company at its meeting held on May 26, 2025, approved the appointment of MRR & Associates, as Secretarial Auditors of the Company, for a term of five consecutive years commencing from FY 2025-26 to FY 2029- 30, subject to approval of the shareholders at the ensuing Annual General Meeting.	
3	Brief Profile (in case of appointment)	M/s. MRR & Associates is a firm of company secretaries in practice. They have experience in delivering comprehensive professional services across Corporate Laws, SEBI Regulations and FEMA Regulations. Their expertise includes conducting Secretarial Audits, Due Diligence Audits, Compliance Audits etc.	
4	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable	

**AUROBINDO PHARMA LIMITED** 

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com